Vectors, systems and methods for eukaryotic gene editing

JP2023550381A5Pending Publication Date: 2024-11-20WAKE FOREST UNIVERSITY HEALTH SCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529965
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-19
Filing Date
2021-11-19
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Adenine base editors (ABEs) exhibit significant guide-independent RNA off-target activity, raising safety concerns and hindering their clinical application in gene therapy for genetic diseases caused by paired mutations.

Method used

A mammalian expression plasmid system is developed, incorporating a eukaryotic promoter linked to a non-viral nucleic acid sequence encoding an adenine base editor (ABE) and a guide RNA (gRNA) with aptamer coding sequences, packaged into lentivirus-like particles that lack a functional integrase protein, to minimize RNA off-target effects.

Benefits of technology

The system significantly reduces RNA off-target activity, enhancing the safety and efficacy of ABE delivery to eukaryotic cells, particularly primary cells, while maintaining efficient genome editing capabilities.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are compositions and methods for editing the genome of eukaryotic cells.In some embodiments, the catalytically impaired CRISPR-associated endonuclease coding sequence encodes Cas9 D10A protein.In some embodiments, the adenine base editor is ABE7.10 or ABE8.In some embodiments, at least one aptamer coding sequence encodes the aptamer sequence that is specifically bound by ABP selected from the group consisting of MS2 coat protein, PP7 coat protein, lambda N RNA binding domain, or Com protein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Prior Related Applications This application claims the benefit of U.S. Provisional Application No. 63 / 115,932, filed November 19, 2020, which is hereby incorporated by reference in its entirety.

[0002] Field The present disclosure describes compositions and methods of using same for eukaryotic gene editing.

[0003] Reference to sequence listings submitted as text files via EFS-Web An official copy of the Sequence Listing has been submitted electronically via EFS-Web as an ASCII-formatted Sequence Listing having a size of 79.0 kb, created on November 15, 2021, under the file name 095199-1275954_seqlist, and is being submitted contemporaneously herewith. The Sequence Listing contained in this ASCII-formatted document is a part of the present specification and is incorporated herein by reference in its entirety. [Background technology]

[0004] background Fusion of adenine deaminase with nuclease-deficient type II CRISPR / Cas9 (clustered regularly interspaced short palindromic repeats / CRISPR-associated 9) creates an adenine base editor (ABE) that can edit genomic DNA without double-stranded DNA breaks. Base editing generates precise point mutations in genomic DNA without generating double-stranded breaks. Furthermore, adenine base editing does not require a DNA donor template and does not rely on cellular homology-directed repair. Therefore, it has great potential as a gene therapy for genetic diseases caused by pairwise mutations, which account for 61% of disease-causing point mutations. Although adenine base editors (ABEs) have been used in many in vitro and in vivo studies, ABEs exhibit significant guide-independent RNA off-target activity, raising safety concerns and hindering their potential clinical application. Therefore, compositions and methods for reducing the RNA off-target activity of ABEs are needed. Summary of the Invention [Means for solving the problem]

[0005] overview Provided herein is a mammalian expression plasmid comprising a eukaryotic promoter operably linked to a non-viral nucleic acid sequence, the non-viral nucleic acid sequence comprising: (i) a nucleic acid sequence encoding an adenosine base pair editor (ABE), wherein the ABE is a fusion protein comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease; and (ii) a guide RNA (gRNA) coding sequence comprising at least one aptamer coding sequence.

[0006] In some embodiments, the catalytically impaired CRISPR-associated endonuclease coding sequence encodes a Cas9 D10A protein. In some embodiments, the adenine base editor is ABE7.10 or ABE8. In some embodiments, the at least one aptamer coding sequence encodes an aptamer sequence that is specifically bound by an ABP selected from the group consisting of MS2 coat protein, PP7 coat protein, lambda N RNA-binding domain, or Com protein. In some embodiments, the aptamer is an MS2 aptamer sequence or a com aptamer sequence. In some embodiments, the sgRNA coding sequence comprises at least one aptamer inserted into the tetraloop or ST2 loop of the sgRNA coding sequence. In some embodiments, the sgRNA coding sequence comprises at least one com aptamer inserted into the ST2 loop of the gRNA coding sequence.

[0007] Also provided is a lentiviral packaging system comprising: (a) a packaging plasmid comprising a eukaryotic promoter operably linked to a Gag nucleotide sequence, wherein the Gag nucleotide sequence comprises a nucleocapsid (NC) coding sequence and a matrix protein (MA) coding sequence, wherein one or both of the NC coding sequence or the MA coding sequence comprises at least one non-viral aptamer binding protein (ABP) nucleotide sequence, and wherein the packaging plasmid does not encode a functional integrase protein; (b) at least one mammalian expression plasmid provided herein; and (c) an envelope plasmid comprising an envelope glycoprotein coding sequence.

[0008] In some embodiments, the packaging plasmid further comprises a Rev nucleotide sequence and a Tat nucleotide sequence. In some embodiments, the system further comprises a second packaging plasmid comprising a Rev nucleotide sequence. In some embodiments, the at least one non-viral ABP nucleotide sequence encodes an MS2 coat protein, a PP7 coat protein, a lambda N peptide, or a Com protein.

[0009] Further provided are lentivirus-like particles comprising: (a) a fusion protein comprising a nucleocapsid (NC) protein or a matrix (MA) protein, wherein the NC protein or the MA protein comprises at least one non-viral aptamer-binding protein (ABP); and (b) a ribonucleotide-protein (RNP) complex comprising (i) an adenine base editor (ABE), which is a fusion polypeptide comprising an adenine base editor and a catalytically impaired CRISPR-associated endonuclease, and (ii) a gRNA, the lentivirus-like particle not comprising a functional integrase protein. In some lentivirus-like particles, the catalytically impaired CRISPR-associated endonuclease is a catalytically impaired Cas9 protein, a catalytically impaired Cpf1 protein, or a derivative of either. In some lentivirus-like particles, the adenine base editor is ABE7.10 or ABE8.

[0010] Also provided is a method for producing lentivirus-like particles, comprising: (a) transfecting a plurality of eukaryotic cells with any of the packaging plasmids of the systems described herein, at least one mammalian expression plasmid, and an envelope plasmid; and (b) culturing the transfected eukaryotic cells for a sufficient time to produce lentivirus-like particles. In some embodiments, the produced lentivirus-like particles comprise (i) an adenine base editor (ABE), which is a fusion polypeptide comprising adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease, and (ii) an RNP comprising a guide RNA. In some embodiments, the plurality of eukaryotic cells are mammalian cells.

[0011] Further provided is a method for modifying a genomic target sequence in a cell, comprising transducing a plurality of eukaryotic cells with a plurality of viral particles described herein, wherein RNP binds to the genomic target sequence in the genomic DNA of the cells, and ABE deaminates adenine in the genomic target sequence, thereby modifying the genomic target sequence. In some methods, the plurality of eukaryotic cells are mammalian cells. In some embodiments, the plurality of eukaryotic cells are cells present in a subject. In some embodiments, the subject is a human subject. In some embodiments, the subject is injected with a plurality of viral particles.

[0012] Also provided are cells comprising any of the plasmids, lentiviral packaging systems, or lentivirus-like particles described herein. Also provided are cells modified by any of the methods provided herein.

[0013] Further provided is a method for treating a disease in a subject, the method comprising: (a) obtaining cells from the subject; and (b) modifying the subject's cells using any of the genome editing methods described herein, and administering the modified cells to the subject. In some embodiments, the disease is cancer. In some embodiments, the disease is sickle cell anemia. In some embodiments, the cells are T cells.

[0014] Text description of the illustration image022.gif. This application includes the following figures. The figures illustrate certain embodiments and / or features of the compositions and methods and are intended to supplement any description of the compositions and methods. The figures do not limit the scope of the compositions and methods unless the specification expressly indicates otherwise. [Brief explanation of the drawings]

[0015] [Figure 1-1] 1A is a diagram showing predicted ABE off-target hotspots in human USP38 mRNA, according to an embodiment of the present disclosure. The predicted hotspots (red) and the primers used for PCR amplification are shown.

[0016] Figure 1B shows the results of RT-PCR and targeted NGS in which high levels of A to G changes in the 440-nt region of the USP38 mRNA region were detected after ABE DNA transfection, according to an embodiment of the present disclosure. The peak above the x-axis was observed in cells transfected with plasmid DNA expressing ABE and sgRNA (targeting ABE site 1). A peak (very low, in the negative area) was observed in control cells (transfected with Cas9 nickase targeting ABE site 1). The highest peak, corresponding to the predicted hotspot (CUACGAA), is shown.

[0017] [Figure 1-2]Figure 1C shows the sequences of the most frequent NGS reads (SEQ ID NOS: 108-117) from cells transfected with plasmid DNA expressing ABE targeting ABE site 1 according to an embodiment of the present disclosure. The predicted RNA off-target hotspot is underlined (highest peak). The A to G transition is indicated. The TA dinucleotide marked by the dashed box corresponds to the second peak marked in Figure 1B. The three shaded alleles do not have an A to G transition in the hotspot, but do have an A to G transition in the second peak. DNA samples were collected 48 hours after treatment.

[0018] [Figure 1-3] Figure ID shows the results of next-generation sequencing (NGS) analysis of on-target base editing at ABE site 1 according to an embodiment of the present disclosure. SEQ ID NO: 118 is shown as the reference sequence. 96.30% of the reads correspond to SEQ ID NO: 118, while SEQ ID NOs: 119 and 120 represent 2.22% and 0.25% of the reads, respectively. Data is shown from cells (2 x 10 cells) treated with 20 μg of ABE RNP and collected 24 hours after electroporation for NGS.

[0019] [Figure 2-1] Figure 2A is an exemplary modification to the sgRNA scaffold for ABE RNP packaging according to an embodiment of the present disclosure (SEQ ID NO: 121). The tetraloop (GAAA) and ST2 loop are indicated by dashed boxes. The core aptamer sequence is underlined, and the additional linker is not. Vertical lines indicate complementary base pairs, and dots indicate non-canonical base pairs. As shown in Figure 3A, the tetraloop and ST2 loop can be replaced with the MS2 aptamer sequence (SEQ ID NO: 122). In another example, the tetraloop or ST2 loop can be replaced with the com aptamer sequence (SEQ ID NO: 123).

[0020] [Figure 2-2]FIG. 2B shows the results of qPCR detecting ABE-g1 RNP activity at ABE site 1, according to an embodiment of the present disclosure. A total of 200 ng of p24 from various LV capsids was used to transduce 2.5×10 HEK293T cells. gDNA was used for qPCR with primer-matched edited sequences. *** indicates p<0.0001, one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. Error bars indicate s.e.m. of triplicates.

[0021] 2C shows the results of qPCR detecting ABE-g5 RNP activity at ABE site 5, according to an embodiment of the present disclosure. *p<0.05, ns=not significant; ANOVA followed by Tukey's multiple comparison test.

[0022] [Figure 2-3] Figure 2D shows NGS analysis of capsid RNP-mediated base editing at ABE site 5 according to an embodiment of the present disclosure. Capsid RNP (10 ng of p24) was used to transduce 2.5 x 10 HEK293T cells. SEQ ID NO: 124 is the reference sequence. Alleles with base editing frequencies >0.2% are listed (SEQ ID NOs: 125-133), and the frequency of A>G changes at different positions is shown below.

[0023] [Figure 3] Figure 3 shows NGS analysis of capsid RNP-mediated base editing at ABE site 1 according to an embodiment of the present disclosure. 2.5 x 10 HEK293T cells were transduced with capsid RNP at an amount of 200 ng of p24. SEQ ID NO: 134 is the reference sequence. Alleles with base editing frequencies >0.1% are listed (SEQ ID NOs: 134-139), and the frequency of A>G changes at different positions is shown below.

[0024] [Figure 4-1]Figure 4A shows that aptamer / aptamer-binding protein (ABP) interactions are required for functional ABE packaging in lentiviral capsids according to embodiments of the present disclosure. 40 ng of p24 (ELISA) ABE-g5 RNP capsids and ABE-g5ST2-com RNP capsids were treated with or without Triton®-X100, and p24 and ABE were detected by Western blotting. The p24 image is from the same blot with irrelevant lanes removed. The asterisk indicates full-length protein.

[0025] FIG. 4B shows an estimation of the amount of ABE protein in LV capsids according to an embodiment of the present disclosure.

[0026] [Figure 4-2] Figure 4C shows the results of qPCR detection of base editing activity of ABE-g5 RNP capsids and ABE-g5ST2-com RNP capsids, according to an embodiment of the present disclosure. 2.5 x 10 HEK293T cells were treated with 200 ng of p24 capsid RNP. After 48 hours, gDNA was extracted and analyzed by PCR to detect base editing at site 5. DNA from cells treated with ABE-g1ST2-com RNP capsid (from Figure 3B) was used as a control to demonstrate site specificity.

[0027] FIG. 4D shows the results of qPCR using known concentrations of plasmid DNA to examine the effect of com addition on PCR detection, according to an embodiment of the present disclosure.

[0028] FIG. 4E shows ABE-g5 RNP and ABE-g5 RNP treated with and without Triton® X-100, according to an embodiment of the present disclosure. ST2-com RT-qPCR comparison of sgRNA levels in RNP capsids is shown. *** indicates p<0.0001 in a Bonferroni post-hoc test after ANOVA.

[0029] [Figure 5-1]5A is a Western blot of ABE levels after transduction of HEK293T cells according to an embodiment of the present disclosure. ABE and β-actin gel images are shown. The arrow indicates the position of the full-length ABE band. The β-actin image demonstrates that all samples had lysate input. Because RNP abundance was unrelated to cell proliferation, normalization was not attempted.

[0030] [Figure 5-2] Figure 5B is a densitometric analysis of proteolysis according to an embodiment of the present disclosure. Only the full-length ABE band was quantified. Half-lives were estimated using a two-phase decay model in GraphPad Prism 5.0.

[0031] [Figure 6] 6 is an NGS analysis of RNA off-targets in capsid-RNP-treated cells at a hotspot in USP38 mRNA, according to an embodiment of the present disclosure. The substitution rates in capsid-RNP (targeting ABE site 1)-treated cells (peaks above the X-axis) and negative control cells treated with nickase (peaks below the X-axis) showed no difference. The A to G conversion rates in both peaks were at background levels. The location of the predicted hotspot is indicated. A representative photograph of one of two experiments is shown. DETAILED DESCRIPTION OF THE INVENTION

[0032] definition As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0033] The use of the terms "including," "comprising," or "having," and variations thereof herein, is meant to encompass the subsequently listed elements and equivalents thereof, as well as additional elements. Embodiments recited as "including," "comprising," or "having" certain elements are also contemplated as "consisting essentially of" and "consisting of" those certain elements. As used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations interpreted in the alternative ("or").

[0034] As used herein, the transitional phrase "consisting essentially of" (and grammatical variations) should be construed to encompass the recited materials or steps "and those which do not materially affect the basic and novel characteristics" of the claimed invention. See In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (emphasis in original); see also MPEP §2111.03. Thus, the term "consisting essentially of," as used herein, should not be construed as equivalent to "comprising."

[0035] The term "nucleic acid" or "nucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), and polymers thereof, in either single-stranded or double-stranded form. When RNA is described, it is understood that the corresponding DNA, in which uridine is represented as thymidine, is also described. Similarly, when DNA is described, the corresponding RNA, in which thymidine is represented by uridine, is also described. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties to the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). Polynucleotides of the present invention also encompass all forms of sequences, including, but not limited to, single-stranded forms, double-stranded forms, hairpins, stem and loop structures, and the like.

[0036] The term "gene" can refer to a segment of DNA involved in producing or encoding a polypeptide chain. This can include regions before and after the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons). Alternatively, the term "gene" can refer to a segment of DNA involved in producing or encoding a non-translated RNA, such as rRNA, tRNA, guide RNA, or microRNA.

[0037] "Treating" refers to any indication of successful treatment or recovery or prevention of a disease, condition, or disorder, including any objective or subjective parameter, such as alleviation; remission; reduction of symptoms, or making the disease state more tolerable to the patient; slowing the rate of degeneration or decline; or making the end point of degeneration less debilitating. The treatment or recovery of symptoms can be based on objective or subjective parameters, including the results of a physician's examination. Thus, the term "treating" includes the administration of a compound, lentivirus-like particle, or agent of the present disclosure to prevent or delay, alleviate, or stop or inhibit the onset of symptoms or conditions associated with the diseases, conditions, or disorders described herein. The term "therapeutic effect" refers to the reduction, elimination, or prevention of the disease, disease symptoms, or disease side effects in a subject. "Treating" or "treatment" using the methods of the present disclosure includes preventing the onset of symptoms, inhibiting (slowing or halting) the symptoms of a disease or disorder, providing relief from the symptoms or side effects of a disease (including palliative care), and alleviating (causing regression) the symptoms of a disease in a subject who may be at increased risk for a disease or disorder associated with a disease, condition, or disorder described herein but who has not yet experienced or displayed symptoms. Treatment can be prophylactic (to prevent or delay the onset of a disease or condition or to prevent the manifestation of clinical or asymptomatic symptoms thereof) or therapeutic suppression or alleviation of symptoms after the manifestation of a disease or condition. The term "treatment," as used herein, includes preventative (e.g., prophylactic) treatment, curative treatment, or palliative care.

[0038] " Promoter " is defined as one or more nucleic acid control sequences that direct the transcription of nucleic acid. As used herein, promoter includes the necessary nucleic acid sequence near the start site of transcription, for example, in the case of polymerase II type promoter, TATA element. Promoter also includes distal enhancer or repressor elements, which may be located several thousand base pairs from the start site of transcription, if necessary.

[0039] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acid residues. All three terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of corresponding naturally occurring amino acids, as well as naturally occurring and non-naturally occurring amino acid polymers. As used herein, the terms encompass full-length proteins, truncated proteins and fragments thereof, and amino acid chains in which amino acid residues are linked by covalent peptide bonds. As used throughout, the term "fusion polypeptide" or "fusion protein" refers to a polypeptide comprising two or more proteins or fragments thereof. In some embodiments, a linker comprising approximately 3-10 amino acids may be positioned between any two proteins or fragments thereof to help facilitate proper folding of the proteins upon expression.

[0040] The term "identity" or "substantial identity," when used in the context of polynucleotide or polypeptide sequences described herein, refers to a sequence having at least 60% sequence identity to a reference sequence. Alternatively, the percent identity can be any integer between 60% and 100%. Exemplary embodiments include at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity when compared to a reference sequence using a program described herein, preferably BLAST using standard parameters as described below. It is understood that any nucleotide or polypeptide sequence set forth herein, for example, a sequence having 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to any one of SEQ ID NOs: 1-48, can be used in the compositions and methods provided herein. It is understood that a nucleic acid sequence can comprise, consist of, or consist essentially of any nucleic acid sequence described herein. Similarly, a polypeptide can comprise, consist of, or consist essentially of any polypeptide sequence described herein. For sequence comparison, typically, one sequence serves as a reference sequence to which a test sequence is compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence relative to the reference sequence based on the program parameters.

[0041] "Comparison window," as used herein, includes reference to any one segment of the number of contiguous positions selected from the group consisting of 20 to 600, about 20 to 50, about 20 to 100, about 50 to about 200, or about 100 to about 150, within which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods for aligning sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed by the local homology algorithm of Smith and Waterman Add. APL. Math. 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman Proc. Natl. Acad. Sci. (USA) 85: 2444 (1988), by computerized implementations of these algorithms (e.g., BLAST), or by manual alignment and visual inspection.

[0042] Suitable algorithms for determining percent sequence identity and percent sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analysis is published by the National Center for Biotechnology Information (NCBI) website. The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short word lengths W in the query sequence that either match or meet some positive threshold score T when aligned with words of the same length in database sequences. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits serve as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction is stopped when the cumulative alignment score falls by an amount X from its reached maximum; when the cumulative score falls to zero or below due to the accumulation of alignments of one or more negative-scoring residues; or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word size (W) of 28, an expectation (E) of 10, M=1, N=-2, and a comparison of both strands.

[0043] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences will occur by chance. For example, the smallest sum probability in a comparison of a test nucleic acid with a reference nucleic acid is less than about 0.01, more preferably less than about 10 -5 less than, most preferably about 10 -20 A nucleic acid is considered to be similar to a reference sequence if it is less than

[0044] As used throughout, subject refers to an individual. For example, the subject is a mammal, such as a primate, more specifically, a human. Non-human primates are also subjects. The term subject includes domestic animals, such as cats, dogs, livestock (e.g., cows, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., ferrets, chinchillas, mice, rabbits, rats, gerbils, guinea pigs, etc.). Therefore, veterinary and medical uses and formulations are contemplated herein. The term does not indicate a specific age or sex. Therefore, adult and newborn subjects are intended to be covered, regardless of whether they are male or female. As used herein, patient or subject may be used interchangeably and may refer to a subject suffering from a disease or disorder.

[0045] An "expression cassette" is a nucleic acid construct, produced recombinantly or synthetically, with a series of specified nucleic acid elements that allow transcription of a particular polynucleotide sequence in a host cell. An expression cassette may be part of a plasmid, a viral genome, or a nucleic acid fragment. Typically, an expression cassette contains a transcribed polynucleotide operably linked to a promoter, followed by a transcription termination signal sequence. An expression cassette may or may not contain specific regulatory sequences, such as 5' or 3' untranslated regions from human globin genes.

[0046] "Reporter genes" encode proteins that are easily detectable due to their biochemical characteristics, such as enzymatic activity or chemiluminescent traits. These reporter proteins can be used as selectable markers. One specific example of such a reporter is green fluorescent protein. The fluorescence produced by this protein can be detected using a variety of commercially available fluorescence detection systems. Other reporters can be detected by staining. A reporter can also be an enzyme that generates a detectable signal upon contact with an appropriate substrate. A reporter can also be an enzyme that catalyzes the formation of a detectable product. Suitable enzymes include, but are not limited to, proteases, nucleases, lipases, phosphatases, and hydrolases. A reporter can encode an enzyme whose substrate is substantially impermeable to eukaryotic cell membranes, thereby allowing tight control over signal generation. Specific examples of suitable reporter genes encoding enzymes include, but are not limited to, CAT (chloramphenicol acetyltransferase; Alton and Vapnek (1979) Nature 282: 864-869); luciferase (lux); β-galactosidase; LacZ; β-glucuronidase; and alkaline phosphatase (Toh, et al. (1980) Eur. J. Biochem. 182: 231-238; and Hall et al. (1983) J. Mol. Appl. Gen. 2: 101), each of which is incorporated herein by reference in its entirety. Other suitable reporters include those encoding specific epitopes that can be detected using a labeled antibody that specifically recognizes the epitope.

[0047] In the compositions and methods provided herein, CRISPR-associated endonuclease is a catalytically impaired nuclease.As used throughout, " catalytically impaired" refers to the reduced CRISPR-associated endonuclease enzyme activity for cutting one or both strands of DNA.Examples of catalytically impaired CRISPR-associated endonuclease include, but are not limited to, catalytically impaired Cas9, catalytically impaired Cpf1, and catalytically impaired C2c2.In some examples, catalytically impaired CRISPR-associated endonuclease is catalytically impaired Cas9, for example, Cas9 D10A, which only cuts or nicks one strand of DNA.In some examples, CRISPR-associated endonuclease can be a catalytically impaired CRISPR-associated endonuclease, where the endonuclease cannot cut both strands of double-stranded DNA molecules, i.e., cannot make double-strand breaks. Modifications include, but are not limited to, changing one or more amino acids to inactivate nuclease activity or nuclease domain. For example, but not limited to, D10A and / or H840A mutations can be made in Cas9 derived from Streptococcus pyogenes to reduce or inactivate Cas9 nuclease activity. Other modifications include removing all or part of the nuclease domain of Cas9 so that the sequence exhibiting nuclease activity is absent from Cas9. Thus, catalytically impaired Cas9 can include a polypeptide sequence modified to reduce nuclease activity or the removal of a polypeptide sequence(s) to reduce nuclease activity. Catalytically impaired Cas9 retains the ability to bind to DNA even when nuclease activity is inactivated. Thus, a catalytically impaired Cas9 contains the polypeptide sequence(s) necessary for DNA binding, but contains an altered nuclease sequence or lacks the nuclease sequence responsible for nuclease activity.It is understood that similar modifications can be made to reduce the nuclease activity of other site-specific nucleases, such as Cpfl or C2c2. In some examples, the Cas9 protein is a full-length Cas9 sequence from S. pyogenes that lacks the polypeptide sequence of the RuvC nuclease domain and / or the HNH nuclease domain and retains DNA-binding function. In other examples, the Cas9 protein sequence has at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% identity to a Cas9 polypeptide sequence that lacks the RuvC nuclease domain and / or the HNH nuclease domain and retains DNA-binding function.

[0048] Examples of catalytically impaired CRISPR-associated endonucleases include, but are not limited to, nucleases present in any bacterial species that encode a type II or type V CRISPR / Cas system. "CRISPR / Cas" systems refer to a broad class of bacterial systems for defense against foreign nucleic acids. CRISPR / Cas systems are found in a wide range of eubacterial and archaeal organisms. CRISPR / Cas systems include type I, type II, and type III subtypes. The classification of CRISPR / Cas systems described by Makarova et al. (Nat Rev Microbiol. 2015 Nov; 13(11):722-36) defines five types and 16 subtypes based on shared characteristics and evolutionary similarities. These are grouped into two major classes based on the structure of the effector complex that cleaves genomic DNA. Type II CRISPR / Cas systems were first used for genome engineering, followed by type V in 2015. Wild-type type II CRISPR / Cas systems utilize an RNA-mediated nuclease Cas protein or homolog (referred to herein as a "CRISPR-associated endonuclease") in complex with a guide RNA to recognize and cleave foreign nucleic acids. The Cas9 protein also uses an activator RNA (also referred to as a trans-activating RNA or tracrRNA). Depending on the type of CRISPR-associated endonuclease used with them, guide RNAs or guide RNAs with both guide RNA and activator RNA activity are also known in the art. In some cases, such dual-activity guide RNAs are referred to as single guide RNAs (sgRNAs). Synthetic guide RNAs that do not contain an activator RNA sequence may also be referred to as sgRNAs. In this disclosure, the terms sgRNA and gRNA are used interchangeably to refer to RNA molecules that complex with a CRISPR-associated endonuclease and localize the ribonucleoprotein complex to a target DNA sequence.

[0049] For example, but not limited to, the CRISPR-associated endonuclease can be a Cas9 polypeptide (type II) or a Cpfl polypeptide (type V). See, e.g., Abudayyeh et al., Science 2016 August 5; 353(6299):aaf5573; Fonfara et al. Nature 532: 517-521 (2016), and Zetsche et al., Cell 163(3): pp. 759-771, 22 October 2015. As used throughout, the term "Cas9 polypeptide" refers to the Cas9 protein or a fragment or derivative thereof identified in any bacterial species that encodes a type II CRISPR / Cas system. See, e.g., Makarova et al. Nature Reviews, Microbiology, 9: 467-477 (2011), the entire contents of which, including supplementary information, are hereby incorporated by reference herein. CRISPR-related endonucleases, such as Cas9 and Cas9 homologues, are found in a wide variety of eubacteria, including but not limited to the following taxonomic groups of bacteria: Actinobacteria, Aquificae, Bacteroidetes-Chlorobi, Chlamydiae-Verrucomicrobia, Chlroflexi, Cyanobacteria, Firmicutes, Proteobacteria, Spirochaetes, and Thermotogae.An exemplary Cas9 protein is Streptococcus pyogenes Cas9 protein (SpCas9).Another exemplary Cas9 protein is Staphylococcus aureus Cas9 protein (SaCas9).Additional Cas9 proteins and homologs thereof are described, for example, in Chylinksi, et al., RNA Biol. 2013 May 1; 10(5): 726-737; Nat. Rev. Microbiol. 2011 June; 9(6): 467-477; Hou, et al., Proc Natl Acad Sci USA. 2013 Sep 24; 110(39): 15644-9; Sampson et al., Nature. 2013 May 9; 497(7448): 254-7; and Jinek, et al., Science. 2012 Aug 17; 337(6096): 816-21. The Cas9 nuclease domain can be optimized for effective activity or enhanced stability in host cells. Other CRISPR-associated endonucleases include Cpf1 (see, e.g., Zetsche et al., Cell, Volume 163, Issue 3, p. 759-771, 22 October 2015) and its homologs.

[0050] Full-length Cas9 is an endonuclease containing a recognition domain that creates a double-strand break in a DNA sequence and two nuclease domains (HNH and RuvC, respectively). In the amino acid sequence of Cas9, HNH is linearly continuous, while RuvC is divided into three regions: one to the left of the recognition domain and two to the right of the recognition domain adjacent to the HNH domain. Cas9 is targeted to genomic sites in cells by interacting with a guide RNA that hybridizes to a 20-nucleotide DNA sequence immediately preceding the NGG motif recognized by Cas9. This results in a double-strand break in the genomic DNA of the cell. In some cases, a Cas9 nuclease can be used that requires an NGG protospacer adjacent motif (PAM) immediately 3' of the region targeted by the guide RNA. As another example, a Cas9 protein with an orthogonal PAM motif requirement can be used to target sequences that do not have an adjacent NGG PAM sequence. Exemplary Cas9 proteins with orthogonal PAM sequence specificity include, but are not limited to, those described in Esvelt et al., Nature Methods 10: 1116-1121 (2013). Various Cas9 nucleases can be utilized in the methods described herein. For example, a Cas9 nuclease that requires an NGG protospacer adjacent motif (PAM) immediately 3' of the region targeted by the guide RNA, such as SpCas9, can be utilized. Such a Cas9 nuclease can be targeted to any region of the genome that contains an NGG sequence. As another example, a Cas9 nuclease that requires an NNGRRT (SEQ ID NO: 79) or NNGRR(N) (SEQ ID NO: 80) PAM immediately 3' of the region targeted by the guide RNA, such as SaCas9, can be utilized. As another example, a Cas9 protein with an orthogonal PAM motif requirement can be utilized to target a sequence that does not have an adjacent NGG PAM sequence.Exemplary Cas9 proteins with orthogonal PAM sequence specificity include, but are not limited to, those described in Esvelt, KM, et al., Nature Methods 10(11): 1116-1121 (2013) and Zetsche et al., Cell, Volume 163, Issue 3, p. 759-771, 22 October 2015.

[0051] In some cases, the catalytically impaired CRISPR-associated endonuclease is Cas9 nickase, for example, Cas9 D10A.In some cases, the Cas9 10A in ABE is encoded by SEQ ID NO: 29.In some cases, the Cas9 10A comprises SEQ ID NO: 30, and generally, when Cas9 nickase is bound to target nucleic acid as a part of a complex with guide RNA, single-strand break or nick is introduced into target nucleic acid.A pair of Cas9 nickases, each bound to structurally different guide RNA, can be targeted to two adjacent sites in target genome region.Exemplary Cas9 nickases include the Cas9 nuclease with D10A or H840A mutation.

[0052] In some embodiments, the CRISPR-associated endonuclease is a catalytically impaired Cpf1 polypeptide. The Cpf1 protein is a class II type V CRISPR / Cas system protein. Cpf1 is a smaller and simpler endonuclease than Cas9 (such as spCas9). The Cpf1 protein has a RuvC-like endonuclease domain similar to the RuvC domain of Cas9, but does not have an HNH endonuclease domain. The N-terminal domain of Cpf1 also does not have an alpha-helix recognition lobe like the Cas9 protein. When cleaving DNA, Cpf1 introduces sticky-end-like DNA double-strand breaks with 4- or 5-nucleotide overhangs. The Cpf1 protein does not require tracrRNA; rather, the Cpf1 protein functions solely through crRNA. In the context of the present disclosure, when the CRISPR-associated endonuclease is a Cpf1 protein, the sgRNA does not contain a tracr sequence. The sgRNA used with the Cpfl protein may contain only the crRNA sequence (constant region). In some examples, a Cpfl protein can be utilized that requires a TTTN or TTN PAM (depending on the species, where "N" is the nucleobase) immediately 5' of the region targeted by the guide RNA. Known Cpfl proteins and their derivatives may be used in the context of the present disclosure. For example, in some examples, the CRISPR-associated endonuclease is FnCpflp, and the PAM is 5'TTN (where N is A / C / G or T). In some examples, the CRISPR-associated endonuclease is PaCpflp, and the PAM is 5'TTTV (where V is A / C or G). In certain examples, the CRISPR-associated endonuclease is FnCpflp, and the PAM is 5'TTN (where N is A / C / G or T), and the PAM is located upstream of the 5' end of the protospacer. In certain examples, the CRISPR-associated endonuclease is FnCpflp, and the PAM is 5'CTA, and is located upstream of the 5' end of the protospacer or at the target locus.In one example, the CRISPR-associated endonuclease is AsCpflp, and the PAM is 5'TTTN.

[0053] As used herein, "activity" in the context of sgRNA activity, or RNP activity, i.e., RNP activity of a complex comprising (1) a gRNA and (2) a fusion protein comprising an ABE and a catalytically impaired CRISPR-associated endonuclease, refers to the ability of the sgRNA to bind to a target gene element. Typically, activity also refers to the ability of the ABE RNP (i.e., the sgRNA complexed with the ABE) to edit base pairs, i.e., make an A to G change in one strand of DNA.

[0054] As used herein, the term "editing" in the context of editing a cell's genome refers to inducing a structural change in the sequence of a genome at a target genomic region, e.g., editing performed by ABE. For example, editing can take the form of an A to G change in one strand of DNA at the target genomic region (or a T to C change in the opposite strand of DNA). The nucleotide sequence can encode a polypeptide or a fragment thereof. See, for example, Gaudelli et al., "Programmable base editing of AT to GC in genomic DNA without DNA cleavage," Nature 551: 464-471 (2017).

[0055] As used herein, "adenine base editor" or "ABE" refers to a fusion protein comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease. In some examples, the adenosine deaminase is a tadA enzyme that deaminates adenine to form inosine on a single strand of DNA. See Gaudelli et al. (2017). In some examples, the ABE is a fusion protein comprising a catalytically impaired CRISPR-associated endonuclease and one or more copies of adenosine deaminase, for example, two, three, four copies, etc. In some examples, the ABE comprises a fusion protein encoded by a nucleic acid sequence comprising SEQ ID NO: 27. In some examples, the ABE comprises SEQ ID NO: 28.

[0056] As used herein, the terms "ribonucleoprotein complex," "RNP," and the like refer to (1) an ABE and a crRNA (e.g., a guide RNA or a single guide RNA), (2) an ABE and a trans-activating crRNA (tracrRNA), (3) an ABE, a catalytically impaired CRISPR-associated endonuclease (e.g., Cas9), and a guide RNA, or (4) a complex between a combination thereof (e.g., a complex containing an ABE and a catalytically impaired CRISPR-associated endonuclease, a tracrRNA, and a crRNA guide).

[0057] As used herein, "cell" can be any eukaryotic cell, for example, human T cell, or cell that can differentiate into T cell, for example, T cell that expresses TCR receptor molecule.These include hematopoietic stem cells and cells derived from hematopoietic stem cells.Also provided herein is a population of cells produced by any of the genome editing methods provided herein, for example, a population of cells that contain virus particles or genetically modified cells.

[0058] As used herein, the phrase "hematopoietic stem cells" refers to a type of stem cell that can give rise to blood cells. Hematopoietic stem cells can give rise to cells of the myeloid or lymphoid lineage, or a combination thereof. Hematopoietic stem cells are primarily found in bone marrow, but they can be isolated from peripheral blood or fractions thereof. Various cell surface markers can be used to identify, select, or purify hematopoietic stem cells. In some cases, hematopoietic stem cells are expressed by the c-kit + and lin - In some cases, human hematopoietic stem cells are identified as CD34 + , CD59 + , Thy1 / CD90 + , CD38 lo / - , C-kit / CD117 + , lin - In some cases, human hematopoietic stem cells are identified as CD34 - , CD59 + , Thy1 / CD90 + , CD38 lo / - , C-kit / CD117 + , lin - In some cases, human hematopoietic stem cells are identified as CD133 + , CD59 + , Thy1 / CD90 + , CD38 lo / - , C-kit / CD117 + , lin - In some cases, mouse hematopoietic stem cells are identified as CD34 lo / - , SCA-1 + , Thy1 + / lo , CD38 + , C-kit + , lin - In some cases, the hematopoietic stem cells are identified as CD150 + CD48 - CD244 - is.

[0059] As used herein, the phrase "hematopoietic cells" refers to cells derived from hematopoietic stem cells. Hematopoietic cells can be obtained or provided by isolation from an organism, system, organ, or tissue (e.g., blood or a fraction thereof). Alternatively, hematopoietic stem cells can be isolated, and hematopoietic cells can be obtained or provided by differentiating the stem cells. Hematopoietic cells include cells with limited potential to differentiate into additional cell types. Such hematopoietic cells include, but are not limited to, multipotent progenitor cells, lineage-restricted progenitor cells, common myeloid progenitor cells, granulocyte-macrophage progenitor cells, or megakaryocyte-erythroid progenitor cells. Hematopoietic cells include cells of the lymphoid and myeloid lineages, such as lymphocytes, erythrocytes, granulocytes, monocytes, and platelets. In some embodiments, the hematopoietic cells are immune cells, such as T cells, B cells, macrophages, natural killer (NK) cells, or dendritic cells. In some embodiments, the cells are innate immune cells.

[0060] As used herein, the phrase "T cells" refers to lymphoid cells that express T cell receptor molecules. T cells include human alpha beta (αβ) T cells and human gamma delta (γδ) T cells. T cells include, but are not limited to, naive T cells, stimulated T cells, primary T cells (e.g., not cultured), cultured T cells, immortalized T cells, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, combinations thereof, or subpopulations thereof. T cells are CD4 + , CD8 + , or CD4 + and CD8 + T cells can also be CD4 - , CD8 - , or CD4 - and CD8 - T cells can be helper cells, e.g., T H 1. T H 2. T H 3. T H 9. T H 17, or T FHThe T cells may be cytotoxic T cells. The regulatory T cells may be FOXP3 + or FOXP3 - The T cells may be alpha / beta T cells or gamma / delta T cells. In some cases, the T cells are CD4 + CD25 hi CD127 lo In some cases, the T cells are type 1 regulatory (Tr1), T H In some cases, the T cells are regulatory T cells selected from the group consisting of FOXP3, CD8+CD28-, Treg17, and Qa-1 restricted T cells, or a combination or subpopulation thereof. + In some cases, the T cells are CD4 + CD25 lo CD127 hi In some cases, the T cells are CD4 + CD25 lo CD127 hi CD45RA hi CD45RO - The T cells are naive T cells. The T cells may be genetically engineered recombinant T cells.

[0061] As used herein, the term "primary" in the context of primary cells refers to cells that are neither transformed nor immortalized. Such primary cells can be cultured, subcultured, or passaged a limited number of times (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 times). In some cases, primary cells are adapted to in vitro culture conditions. In some cases, primary cells are isolated from organisms, systems, organs, or tissues, optionally selected, and used directly without culturing or subculture. In some cases, primary cells are stimulated, activated, or differentiated. For example, primary T cells can be activated by contact with (e.g., culturing in the presence of) CD3, CD28 agonist, IL-2, IFN-γ, or a combination thereof.

[0062] Detailed Description The following description lists various aspects and embodiments of the present compositions and methods. The specific embodiments are not intended to define the scope of the compositions and methods. Rather, the embodiments merely provide non-limiting examples of various compositions and methods that are at least within the scope of the disclosed compositions and methods. The description should be read from the perspective of a person skilled in the art, and therefore does not necessarily include information that is known to a person skilled in the art.

[0063] Provided herein are compositions, systems, manufacturing methods, and methods for the efficient delivery of adenine base editors (ABEs) into eukaryotic cells using viral particles. Using the compositions and methods described herein, ABEs can be efficiently delivered into eukaryotic cells while minimizing RNA off-target effects unrelated to the sgRNA. For example, components, systems, manufacturing methods, and methods are provided for the efficient delivery of (1) an adenosine base pair editor (ABE), a fusion protein comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease, and (2) an RNP containing an sgRNA into cells via lentivirus-like particles. The RNPs described herein have a limited half-life, thus reducing the risk of RNA and DNA off-target-mediated mutagenesis. Delivery of RNPs into eukaryotic cells allows for efficient delivery, for example, in cells that are difficult to transfect, such as primary cells, while reducing off-target effects.

[0064] Mammalian expression plasmids The present disclosure provides a mammalian expression plasmid that is used to deliver CRISPR component coding sequences, i.e., sgRNA and ABE, to mammalian cells to produce the lentivirus-like particles of the present disclosure.For example, the present disclosure provides a mammalian expression plasmid that comprises a eukaryotic promoter operably linked to a non-viral nucleic acid sequence, wherein the non-viral nucleic acid sequence comprises: (i) a nucleic acid sequence encoding an adenosine base pair editor (ABE), wherein the ABE is a fusion protein comprising adenosine deaminase and catalytically impaired CRISPR-associated endonuclease, and (ii) a guide RNA (gRNA) coding sequence that comprises at least one aptamer coding sequence.

[0065] In the mammalian expression plasmids described herein, one or more copies of ABE can be fused or linked to a catalytically impaired CRISPR-associated endonuclease. Optionally, the site-specific nuclease is linked to the adenine base editor via a peptide linker. The linker can be about 2 to about 25 amino acids in length. In some examples, the adenine base editor can be ABE7 (e.g., ABE7.10 (Gaudelli et al. (2017), ABE6.3, ABE7.8, or ABE7.9) or ABE8 adenine base editor (Gaudelli et al., "Directed evolution of adenine base editors with increased activity and therapeutic application," Nature Biotechnology 38: 892-900 (2020)).

[0066] The mammalian expression plasmids provided herein include CRISPR component coding sequences, such as coding sequences for a catalytically impaired CRISPR-associated endonuclease and a gRNA. In some examples, the gRNA coding sequence includes at least one aptamer coding sequence. In some examples, the at least one aptamer coding sequence may be located at the 5' or 3' end of the gRNA. In some examples, the at least one aptamer coding sequence may be inserted into an internal position within the gRNA, such as one or more of the loops formed in the folded gRNA. For example, if the gRNA is for a Cas9 protein, the at least one aptamer coding sequence may be located in the tetraloop, stem loop 2 (ST2), or 3' end of the gRNA. In some examples, a spacer of 1 to 30 nucleotides may be located between or adjacent to the at least one aptamer coding sequence of the gRNA.

[0067] In some examples, the mammalian expression vector includes at least one aptamer coding sequence encoding an aptamer sequence specifically bound by an aptamer-binding protein (ABP). In the context of the present disclosure, an aptamer sequence is an RNA sequence that forms a tertiary loop structure specifically bound by an ABP. An ABP is an RNA-binding protein or an RNA-binding protein domain. Suitable aptamer coding sequences include polynucleotide sequences encoding known bacteriophage aptamer sequences. Exemplary aptamer coding sequences include those encoding the aptamer sequences provided in Table 1 above. In some examples, the aptamer is bound by a dimer of an ABP. These aptamer sequences are RNA sequences known to be specifically bound by bacteriophage proteins. In some situations, at least one aptamer coding sequence encodes an aptamer sequence specifically bound by an ABP selected from the group consisting of MS2 coat protein, PP7 coat protein, lambda N RNA-binding domain, or Com protein. Table 1. Aptamer-binding proteins and corresponding aptamer sequences [Table 1]

[0068] In some cases, the mammalian expression vector comprises an sgRNA that comprises one aptamer coding sequence downstream thereof.In other cases, the gRNA can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 aptamer coding sequences.For example, in some cases, the gRNA can comprise two aptamer coding sequences in tandem.

[0069] As used throughout, sgRNA refers to a single guide RNA sequence that interacts with a CRISPR-associated endonuclease (CRISPR site-specific nuclease) and specifically binds to or hybridizes with a target nucleic acid (genomic target sequence) within a cell's genome, resulting in co-localization of the sgRNA and CRISPR-associated endonuclease to the target nucleic acid in the cell's genome. Each sgRNA contains a DNA targeting sequence or protospacer sequence approximately 10-50 nucleotides long that specifically binds to or hybridizes with a target DNA sequence in the genome. For example, the DNA-targeting sequence can be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. For example, the DNA-targeting sequence can be about 15-30 nucleotides, about 15-25 nucleotides, about 10-25 nucleotides, or about 18-23 nucleotides. In one example, the DNA-targeting sequence is about 20 nucleotides. In some embodiments, the sgRNA comprises a crRNA sequence and a transactivating crRNA (tracrRNA) sequence. In some embodiments, the sgRNA does not comprise a tracrRNA sequence.

[0070] Generally, DNA targeting sequences are designed to be complementary (e.g., perfectly complementary) or substantially complementary (e.g., with 1 to 4 mismatches) to the target DNA sequence. In some cases, DNA targeting sequences can incorporate wobble bases or degenerate bases to bind multiple genetic elements. In some cases, the 3'- or 5'-terminal 19 nucleotides of the binding region are perfectly complementary to the target genetic element(s). In some cases, the binding region can be modified to increase stability. For example, non-natural nucleotides can be incorporated to increase RNA resistance to degradation. In some cases, the binding region can be modified or designed to avoid or reduce secondary structure formation in the binding region. In some cases, the binding region can be designed to optimize GC content. In some cases, the GC content is preferably about 40% to about 60% (e.g., 40%, 45%, 50%, 55%, 60%). In some cases, the binding region can be selected to begin with a sequence that facilitates efficient transcription of the sgRNA. For example, the binding region may start at the 5' end with a G nucleotide. In some cases, the binding region may contain modified nucleotides, such as, but not limited to, methylated or phosphorylated nucleotides.

[0071] As used herein, the terms "complementary" or "complementarity" refer to base pairing between nucleotides or nucleic acids, for example, but not limited to, base pairing between an sgRNA and a target sequence. Complementary nucleotides are generally A and T (or A and U), and G and C. The guide RNAs described herein can include sequences that are fully complementary or substantially complementary (e.g., with 1-4 mismatches) to a genomic sequence, e.g., a DNA targeting sequence.

[0072] The sgRNA comprises an sgRNA constant region that interacts with or binds to a CRISPR-associated endonuclease. In the constructs provided herein, the constant region of the sgRNA can be approximately 75 to 250 nucleotides in length. In some examples, the constant region is a modified constant region containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleotide substitutions in the stem, stem-loop, hairpin, inter-hairpin region, and / or constant region nexus. In some examples, modified constant regions having at least 80%, 85%, 90%, or 95% of the activity of the native or wild-type sgRNA constant region from which the modified constant region is derived can be used in the constructs described herein. In particular, modifications should not be made to nucleotides that directly interact with the CRISPR-associated endonuclease or to nucleotides that are important for the secondary structure of the constant region.

[0073] The mammalian expression plasmid comprises the eukaryotic promoter that is operably linked to the non-viral nucleic acid sequence.In some examples, the RNA polymerase II promoter is operably linked to the catalytically impaired CRISPR-associated endonuclease coding sequence, and the RNA polymerase III promoter is operably linked to the gRNA coding sequence.

[0074] The RNA polymerase II promoter sequence is selected from a mammalian species. The RNA polymerase III promoter sequence is selected from a mammalian species. For example, these promoter sequences can be selected from human, bovine, ovine, buffalo, porcine, or murine, to name a few. In some examples, the RNA polymerase II promoter sequence is a CMV, FE1α, or SV40 sequence. In some examples, the RNA polymerase III promoter sequence is a U6 or H1 sequence. In some examples, the RNA polymerase II sequence is a modified RNA polymerase II sequence. For example, an RNA polymerase II sequence having at least 80%, 85%, 90%, 95%, or 99% identity to a wild-type RNA polymerase II promoter sequence from any mammalian species can be used in the constructs provided herein. In some examples, the RNA polymerase III sequence is a modified RNA polymerase III sequence. For example, RNA polymerase III sequences having at least 80%, 85%, 90%, 95%, or 99% identity to wild-type RNA polymerase III promoter sequences from any mammalian species can be used in the constructs provided herein. Those skilled in the art will readily understand how to determine the identity of two polypeptides or nucleic acids. For example, identity can be calculated after aligning the two sequences so that the identity is at its highest level. Another way to calculate identity can be by using a published algorithm. For example, optimal alignment of sequences for comparison can be performed using the algorithm of Needleman and Wunsch, J. Mol. Biol. 48(3): 443-453 (1970). In some cases, the eukaryotic promoter is an inducible promoter or a regulatable promoter.

[0075] Coding sequences transcribed from RNA pol II promoters contain a poly(A) signal and a transcription terminator sequence downstream of the coding sequence. Commonly used mammalian terminators (SV40, hGH, BGH, and rbGlob) contain the sequence motif AAUAAA (SEQ ID NO: 81), which promotes both polyadenylation and termination. Coding sequences transcribed from RNA pol III promoters contain a simple run of T residues downstream of the coding sequence as a terminator sequence. The role of a sequence-based element, the terminator, is to define the end of a transcription unit (such as a gene) and initiate the process of releasing newly synthesized RNA from the transcription machinery. Terminators are found downstream of transcribed genes and are typically located immediately after any 3' regulatory elements, such as polyadenylation or poly(A) signals.

[0076] In some examples, the mammalian expression plasmid may also include at least one polynucleotide sequence encoding an RNA stabilizing sequence located downstream of the CRISPR component coding sequence, or downstream of the aptamer coding sequence if located downstream of the CRISPR component coding sequence. The polynucleotide sequence encoding the RNA stabilizing sequence is transcribed downstream of the CRISPR / Cas system component coding sequence and stabilizes the lifespan of the transcribed RNA sequence. In one example, the polynucleotide sequence encoding the RNA stabilizing sequence is located downstream of the catalytically impaired CRISPR-associated endonuclease coding sequence. In another example, the polynucleotide sequence encoding the RNA stabilizing sequence is located downstream of the gRNA coding sequence. An exemplary RNA stabilizing sequence is the sequence of the 3'UTR of the human beta globin gene shown in SEQ ID NO: 17 (DNA) and SEQ ID NO: 18 (RNA). Another example of an RNA stabilizing sequence is SEQ ID NO: 34, which contains two copies of SEQ ID NO: 17. Other RNA stabilizing sequences are described in Hayashi, T. et al., Developmental Dynamics 239(7):2034-2040 (2010) and Newbury, S. et al., Cell 48(2):297-310 (1987). In some cases, a spacer of 1 to 30 nucleotides may be located between the CRISPR component coding sequence and at least one polynucleotide sequence encoding the RNA stabilizing sequence.

[0077] In some examples, the mammalian expression plasmid may contain one or more expression cassettes. In some examples, the mammalian expression plasmid may contain a first expression cassette encoding an ABE and a second expression cassette encoding a gRNA comprising at least one aptamer. In some examples, the mammalian expression plasmid may also contain a reporter gene.

[0078] system Another aspect of the present disclosure is a lentiviral packaging system. Such systems include the mammalian expression plasmids described in this disclosure. These systems are useful in providing components for introduction into mammalian cells to generate the lentivirus-like particles described in this disclosure.

[0079] In some examples, the system includes a lentiviral packaging plasmid comprising a eukaryotic promoter operably linked to a viral sequence, e.g., a Gag nucleotide sequence, wherein the Gag nucleotide sequence comprises a nucleocapsid (NC) coding sequence and a matrix protein (MA) coding sequence, wherein one or both of the NC coding sequence or the MA coding sequence comprises at least one non-viral aptamer binding protein (ABP) nucleotide sequence, and wherein the packaging plasmid does not encode a functional integrase protein.

[0080] For example, provided herein is a lentiviral packaging system comprising: (a) a packaging plasmid comprising a eukaryotic promoter operably linked to a Gag nucleotide sequence, wherein the Gag nucleotide sequence comprises a nucleocapsid (NC)-coding sequence and a matrix protein (MA)-coding sequence, wherein one or both of the NC-coding sequence or the MA-coding sequence comprises at least one non-viral aptamer-binding protein (ABP) nucleotide sequence, and wherein the packaging plasmid does not encode a functional integrase protein; (b) (i) a nucleic acid sequence encoding an adenosine base pair editor (ABE), wherein the ABE is a fusion protein comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease; and (ii) at least one mammalian expression plasmid comprising a gRNA described herein; and (c) an envelope plasmid comprising an envelope glycoprotein-coding sequence.

[0081] The system may include a second-generation packaging plasmid or a third-generation packaging plasmid, or a modified version thereof. In some examples, the packaging plasmid includes the Gag nucleotide sequence described above and further includes a Rev nucleotide sequence and a Tat nucleotide sequence. In other examples, the system includes a first packaging plasmid including the Gag nucleotide sequence described above and a second packaging plasmid including a Rev nucleotide sequence. In each of the packaging plasmids, the viral protein coding sequence is operably linked to a eukaryotic promoter, for example, each individual promoter or one promoter for multiple protein coding sequences. The system may include a second-generation packaging plasmid or a third-generation packaging plasmid, or a modified version thereof.

[0082] In some cases, the ABP coding sequence is located at the 5' or 3' end of the viral protein coding sequence, i.e., the 5' or 3' end of the NC coding sequence or the MA coding sequence. In some cases, the ABP coding sequence can be inserted into the viral protein coding sequence so that the encoded ABP is fused to the viral protein. The ABP coding sequence can be inserted in-frame at an internal position within the viral protein coding sequence. When located in-frame at an internal position near the 5' or 3' end of the viral protein coding sequence, the ABP coding sequence is positioned so as not to disrupt processing sequences such as those described in Tritch, RJ et al., J. Virol. 65(2):922-30 (1991) and Scarlata, S. and Carter, C., Biochimica et Biophysica Acta - Biomembranes 1614(1):62-72 (2003), the entire contents of which are incorporated herein by reference. For example, the Gag nucleotide sequence encodes, among other things, the NC and MA coding sequences, and the Gag precursor protein is processed into separate mature viral proteins by proteolytic cleavage. In-frame insertion of an ABP coding sequence will not disrupt the nucleotides encoding the processing sequences for proteolytic cleavage. In some cases, nucleotides in the viral protein coding sequence may be replaced with the ABP protein coding sequence. In some cases, a linker sequence encoding 3-6 amino acids may be located between the viral protein coding sequence and the ABP coding sequence or adjacent to the ABP coding sequence to help facilitate proper folding of the protein domains during expression.

[0083] In one example, the modified viral protein is NC, and the ABP coding sequence is inserted at the 5' or 3' end of the NC coding sequence. In another example, the modified viral protein is NC, and the ABP coding sequence is inserted before or after one of the zinc finger (ZF) domains. For example, the ABP coding sequence can be inserted after the last codon of the second ZF (ZF2) domain. In another example, the ABP coding sequence can be inserted before the first codon of the ZF2 domain. In another example, the ABP coding sequence can be inserted before the first codon of the first ZF (ZF1) domain. In another example, the ABP coding sequence can be inserted after the last codon of the first ZF (ZF1) domain. In some examples, the ABP coding sequence is inserted into the NC coding sequence in a manner that does not disrupt the highly positive stretch of amino acids in the NC protein.

[0084] In another example, the modified viral protein is MA, and the ABP coding sequence is inserted at the 5' or 3' end of the MA coding sequence. In another example, the ABP coding sequence is inserted in-frame at an internal position within the MA coding sequence. In some examples, nucleotides in the MA coding sequence can be replaced with the ABP protein coding sequence. For example, nucleotides encoding amino acids 44 to 132 of the MA protein can be replaced with the ABP coding sequence. In another example, the ABP coding sequence is inserted before the codon encoding amino acid 44 of the MA protein. In another example, the ABP coding sequence is inserted after the codon encoding amino acid 132 of the MA protein.

[0085] In some examples, the system includes a packaging plasmid comprising a eukaryotic promoter operably linked to a NEF coding sequence or a VPR coding sequence, wherein the NEF coding sequence or the VPR coding sequence comprises at least one non-viral ABP nucleotide sequence. The system may include a second-generation packaging plasmid or a third-generation packaging plasmid, or a modified version thereof. In some examples, the packaging plasmid comprises a Gag nucleotide sequence, a Rev nucleotide sequence, and a Tat nucleotide sequence. In other examples, the system includes a first packaging plasmid comprising a Gag nucleotide sequence and a second packaging plasmid comprising a Rev nucleotide sequence.

[0086] In some examples, the modified viral protein is VPR, and the ABP coding sequence is inserted at the 5' or 3' end of the VPR coding sequence. In one example, the ABP coding sequence is inserted at the 5' end of the VPR coding sequence.

[0087] In another example, the modified viral protein is NEF and the ABP coding sequence is inserted at the 5' or 3' end of the NEF coding sequence. In one example, the ABP coding sequence is inserted at the 3' end of the NEF coding sequence.

[0088] In some examples, the coding sequence of the viral protein may be one of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 25. In some examples, the amino acid sequence of the viral protein may be one of SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26. In some examples, the lentiviral packaging plasmid comprises a sequence encoding at least one of SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26 operably linked to a eukaryotic promoter. In some examples, when the viral protein is NEF, the polypeptide may include three mutations that enhance packaging in the viral capsid, such as the following substitution mutations: G3C, V153L, and E177G.

[0089] In some examples, the plasmid may encode one or more viral proteins, including two or more aptamer-binding proteins fused thereto. In certain examples, the Gag nucleotide sequence of the lentiviral packaging plasmid may include an NC coding sequence and an MA coding sequence, and one or both of the NC coding sequence and the MA coding sequence may include a first non-viral ABP nucleotide sequence and a second non-viral ABP nucleotide sequence. The first non-viral ABP nucleotide sequence and the second non-viral ABP nucleotide sequence may both encode the same ABP. Alternatively, the first non-viral ABP nucleotide sequence and the second non-viral ABP nucleotide sequence encode different ABPs. In some examples, the Gag nucleotide sequence of the lentiviral packaging plasmid may include an NC coding sequence including at least one first non-viral ABP nucleotide sequence and an MA coding sequence including at least one second non-viral ABP nucleotide sequence. The at least one first non-viral ABP nucleotide sequence and the at least one second non-viral ABP nucleotide sequence may both encode the same ABP. Alternatively, the at least one first non-viral ABP nucleotide sequence and the at least one second non-viral ABP nucleotide sequence encode different ABPs.

[0090] In certain examples, the packaging plasmid may encode a VPR or NEF coding sequence, wherein the VPR or NEF coding sequence comprises a first non-viral ABP nucleotide sequence and a second non-viral ABP nucleotide sequence. The first and second non-viral ABP nucleotide sequences may both encode the same ABP. Alternatively, the first and second non-viral ABP nucleotide sequences encode different ABPs.

[0091] Non-viral aptamer-binding protein (ABP) nucleotide sequences encode polypeptide sequences that bind to RNA aptamer sequences. Several non-viral ABPs are suitable for use in the present disclosure. Particularly suitable ABPs include bacteriophage RNA-binding proteins that specifically bind to RNA sequences that form stem-loop structures called RNA aptamer sequences. Exemplary non-viral aptamer-binding proteins include MS2 coat protein, PP7 coat protein, lambda N peptide, and Com (Control of mom) protein. The lambda N peptide can be amino acids 1-22 of the lambda N protein, which is the RNA-binding domain of the protein. In some examples, ABPs bind to their aptamers as dimers. Information about these ABPs and the aptamer sequences to which they bind is provided in Table 1. In some embodiments, at least one non-viral ABP nucleotide sequence encodes a polypeptide having a sequence set forth in any of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16. In some embodiments, the at least one non-viral ABP nucleotide sequence comprises any of SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, or SEQ ID NO:15.

[0092] A feature of the lentiviral packaging plasmids provided herein is that they cannot encode a functional integrase protein. When packaging plasmids do not encode a functional integrase protein and are used in the systems and methods described herein, the risk of the nucleic acid molecules carried by the lentivirus-like particles produced using these packaging plasmids being integrated into the genome of the transduced eukaryotic cell is substantially reduced. In some cases, the lentiviral packaging plasmid contains an integrase coding sequence with an integrase-inactivating mutation therein. For example, the integrase-inactivating mutation can be an aspartic acid to valine mutation (D64V) at amino acid position 64 of the integrase protein encoded by the integrase coding sequence. In some cases, the lentiviral packaging plasmid contains a deletion of all or part of the integrase coding sequence.

[0093] In some embodiments, the lentiviral packaging plasmid comprises a eukaryotic promoter operably linked to a Gag nucleotide sequence. In some embodiments, the mammalian expression plasmid comprises a eukaryotic promoter operably linked to a VPR coding sequence or a NEF coding sequence. In some examples, the eukaryotic promoter is an RNA polymerase II promoter. The RNA polymerase II promoter sequence is selected from a mammalian species. For example, the promoter sequence can be selected from human, bovine, ovine, buffalo, porcine, or murine, to name a few. In some examples, the RNA polymerase II promoter sequence is a CMV, FE1α, or SV40 sequence. In some examples, the RNA polymerase II sequence is a modified RNA polymerase II sequence. For example, an RNA polymerase II sequence having at least 80%, 85%, 90%, 95%, or 99% identity to a wild-type RNA polymerase II promoter sequence from any mammalian species can be used in the constructs provided herein. One of ordinary skill in the art will readily understand how to determine the identity of two polypeptides or nucleic acids. For example, identity can be calculated after aligning the two sequences so that identity is at its highest level. Another way to calculate identity can be by using a published algorithm. For example, optimal alignment of the sequences for comparison can be performed using the algorithm of Needleman and Wunsch, J. Mol. Biol. 48: 443 (1970). In some cases, the eukaryotic promoter is an inducible promoter.

[0094] Coding sequences transcribed from RNA pol II promoters contain a poly(A) signal and a transcription terminator sequence downstream of the coding sequence. Commonly used mammalian terminators (e.g., SV40, hGH, BGH, and rbGlob) contain the sequence motif AAUAAA, which promotes both polyadenylation and termination. The role of a terminator, a sequence-based element, is to define the end of a transcription unit (such as a gene) and initiate the process of releasing newly synthesized RNA from the transcription machinery. Terminators are found downstream of transcribed genes and typically occur immediately after any 3' regulatory elements, such as polyadenylation or poly(A) signals.

[0095] In some examples, the lentiviral packaging plasmid may contain one or more expression cassettes.

[0096] The system can also include an envelope plasmid having an envelope coding sequence encoding a viral envelope glycoprotein. For example, the Env nucleotide sequence can encode VSV-G. The envelope coding sequence is operably linked to a eukaryotic promoter. Suitable eukaryotic promoters are described above. In some instances, the eukaryotic promoter is an RNA pol II promoter.

[0097] The system may include any of the packaging plasmids, envelope plasmids, and mammalian expression plasmids described herein, i.e., a mammalian expression plasmid containing (i) a nucleic acid sequence encoding an ABE, and (ii) a gRNA containing at least one aptamer. When any of the packaging plasmids, mammalian expression plasmids, and envelope plasmids described herein are delivered to eukaryotic cells as a system, the gRNA expressed by the mammalian expression plasmid forms a complex with the catalytically impaired CRISPR-associated endonuclease expressed by the mammalian expression plasmid to form an RNP that is packaged by viral particles produced by the eukaryotic cell through the interaction between the aptamer fused or linked to the gRNA and the ABP linked to a viral protein expressed by the packaging plasmid.

[0098] Also provided herein are kits that include components of the systems described in this disclosure. In some embodiments, the kits include one or more of the plasmids described herein.

[0099] Lentivirus-like particles In another aspect, a lentivirus-like particle is provided, for example, a lentivirus-like particle produced by any of the methods described herein. As used herein, a lentivirus-like particle is a multiprotein structure that mimics the organization and conformation of an authentic native virus but lacks a viral genome. Multiple lentivirus-like particles are also provided. The lentivirus-like particle contains modified lentiviral proteins that are fusion proteins in which at least one aptamer-binding protein is fused to one or more viral proteins. In the context of the present disclosure, the modified viral proteins can be structural or nonstructural. Exemplary structural proteins are the lentiviral nucleocapsid (NC) protein and matrix (MA) protein. Exemplary nonstructural proteins are viral protein R (VPR) and negative regulatory factor (NEF). In some examples, the particle contains a fusion protein comprising the NC protein and the MA protein, one or both of which are fused to at least one nonviral aptamer-binding protein (ABP). The NC protein of the particle may have two functional zinc finger protein domains. In particular, retention of the second NC zinc finger domain may maintain the efficiency of viral assembly and budding. In some examples, the particle contains a fusion protein including a VPR protein or a NEF protein, where the VPR protein or the NEF protein is fused with at least one non-viral ABP. The particle also contains (i) an adenosine base pair editor (ABE), which is a fusion protein including an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease, and (ii) an RNP including a gRNA. Lentivirus-like particles containing RNPs can be produced using any of the mammalian expression plasmids described herein, which contain non-viral nucleic acid sequences and in which at least one aptamer is attached to or inserted into the gRNA sequence. In some examples, the lentivirus-like particles do not contain a functional integrase protein. These virus-like particles are useful for transducing eukaryotic cells of interest.

[0100] The particle may contain a viral fusion protein containing one or more ABPs. In some examples, the particle contains an NC protein, an MA protein, or both, and one or both of the NC protein or the MA protein is fused with one or more non-viral ABPs. In some examples, the lentivirus-like particle contains an NC protein fused with at least one non-viral ABP. In some examples, the lentivirus-like particle contains an MA protein fused with at least one non-viral ABP. In some examples, the lentivirus-like particle may contain an NC protein and an MA protein, and one or both of the NC protein or the MA protein may be fused with two non-viral ABP proteins, a first non-viral ABP, and a second non-viral ABP fused to the C'-terminus of the first non-viral ABP (i.e., in tandem). In certain examples, the particle may contain one or both of the NC protein or the MA protein fused with a first non-viral ABP and a second non-viral ABP.

[0101] In some examples, the lentivirus-like particle contains a VPR protein or a NEF protein, and the VPR protein or the NEF protein is fused to one or more non-viral ABPs. In some examples, the lentivirus-like particle contains two non-viral ABPs, a first non-viral ABP, and a VPR protein or a NEF protein fused to a second non-viral ABP fused to the C'-terminus of the first non-viral ABP (i.e., in tandem). In some examples, the lentivirus-like particle contains a VPR protein or a NEF protein fused to a first non-viral ABP and a second non-viral ABP. The first non-viral ABP and the second non-viral ABP can both be the same ABP. Alternatively, the first non-viral ABP and the second non-viral ABP can be different ABPs. In some examples, the lentivirus-like particle can include an NC protein with at least one first non-viral ABP fused to an MA protein with at least one second non-viral ABP fused to its C'-terminus. The at least one first non-viral ABP and the at least one second non-viral ABP are the same ABP. Alternatively, the at least one first non-viral ABP protein and the at least one second non-viral ABP can be different ABPs. The first non-viral ABP and the second non-viral ABP can be the same ABP. Alternatively, the first non-viral ABP and the second non-viral ABP can be different ABPs.

[0102] Non-viral ABPs are polypeptide sequences that bind to RNA aptamer sequences. Several non-viral ABPs are suitable for use in the present disclosure. Particularly suitable ABPs include bacteriophage RNA-binding proteins that specifically bind to known RNA aptamer sequences, which are RNA sequences that form stem-loop structures. Exemplary non-viral aptamer-binding proteins include MS2 coat protein, PP7 coat protein, lambda N peptide, and Com (regulatory of mom) protein. The lambda N peptide can be amino acids 1-22 of the lambda N protein, which is the RNA-binding domain of the protein. Information about these ABPs and the aptamer sequences to which they bind is provided in Table 1 above.

[0103] Lentivirus-like particles may contain various lentiviral proteins. However, in some cases, lentivirus-like particles do not contain all of the proteins or nucleic acids found in native lentiviruses. In some cases, particles may contain NC, MA, CA, SP1, SP2, P6, POL, ENV, TAT, REV, VIF, VPU, VPR, and / or NEF proteins, or any derivative, combination, or portion thereof. In some cases, particles may contain NC, MA, CA, SP1, SP2, P6, and POL. In some cases, lentivirus-like particles may contain only proteins that form the viral shell (capsid). In some cases, one or more lentiviral proteins may be completely or partially excluded from the lentivirus-like particle. For example, in some cases, lentivirus-like particles may not contain the POL protein, or may contain a non-functional version of the POL protein, such as a POL protein with an inactivating point mutation or truncation. In another example, a lentivirus-like particle may not contain an integrase protein or may comprise a non-functional version of an integrase protein, such as an integrase protein with an inactivating point mutation or truncation. For example, a lentivirus-like particle may contain a non-functional integrase protein with an aspartic acid to valine mutation at amino acid position 64 (D64V). In another example, a lentivirus-like particle may not contain a reverse transcriptase protein or may comprise a non-functional version of a reverse transcriptase protein, such as an integrase protein with an inactivating point mutation or truncation.

[0104] As shown above, gRNA generally comprises a DNA targeting sequence and a constant region that interacts with CRISPR-associated endonuclease.In some cases, gRNA may comprise a transactivating crRNA (tracrRNA) sequence.For example, gRNA may comprise a tracrRNA that is used in conjunction with Cas9 protein or derivative.In other cases, gRNA does not comprise a tracrRNA sequence.For example, gRNA may not comprise a tracrRNA sequence that is used in conjunction with Cpf1 protein or derivative.

[0105] In some examples, the gRNA includes at least one aptamer sequence. In some examples, the at least one aptamer sequence may be located at the 5' or 3' end of the gRNA. In some examples, the at least one aptamer sequence may be inserted at an internal position within the gRNA, such as one or more of the loops formed in the folded gRNA. For example, if the gRNA is for a Cas9 protein, the at least one aptamer sequence may be located in the tetraloop, stem loop 2 (ST2), or 3' end of the gRNA. In some examples, a spacer of 1 to 30 ribonucleotides may be located between the gRNA and the at least one aptamer sequence or adjacent to the at least one aptamer sequence. In certain examples, the at least one aptamer sequence does not interfere with lentivirus-like particle transduction of eukaryotic cells. For example, at least one non-viral ABP fused to one or more of the NC protein, MA protein, VPR protein, or NEF protein cannot interfere with lentivirus-like particle transduction of eukaryotic cells.

[0106] Gene editing methods Described herein are methods of using the plasmids and systems provided in this disclosure in CRISPR / Cas systems to edit DNA targets, e.g., genes, in the genome of eukaryotic cells.

[0107] In the methods provided herein, eukaryotic cells containing a target genomic sequence of interest to be modified are transduced with a lentivirus-like particle containing a viral fusion protein comprising a viral protein fused to at least one aptamer-binding protein (ABP), and an RNP comprising (1) a gRNA, and (2) an adenosine base pair editor (ABE), a fusion protein comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease.

[0108] The advantage of the provided method is the reduction of guide-independent RNA off-target gene editing events associated with ABE.For example, in the method provided herein, guide-independent RNA off-target activity can be reduced by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 95%, 99% or more compared to the RNA off-target activity when RNP is delivered using non-lentivirus delivery.In some cases, guide-independent DNA off-target gene editing events are also reduced.For example, in the method provided herein, guide-dependent DNA off-target activity can be reduced by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 95%, 99% or more compared to the RNA off-target activity when RNP is delivered using non-lentivirus delivery.In addition, when lentivirus-like particles that lack integrase activity are used in the method, there is a reduced risk of any of the nucleic acids carried by the particle being integrated into the cellular genome. In some cases, the lentiviral particles used lack the lentiviral genome sequence part that is essential for viral replication, thus reducing the risk of continued particle production.Another advantage of provided components is that viral fusion protein can increase the packaging of RNP into lentivirus-like particles, and then increase genome editing efficiency.

[0109] In some examples, the transduced eukaryotic cells are mammalian cells. In some examples, the eukaryotic cells can be in vitro cultured cells. In some examples, the eukaryotic cells can be ex vivo cells obtained from a subject. In other examples, the eukaryotic cells are present in a subject. As used throughout, subject refers to an individual. For example, the subject is a mammal, such as a primate, more specifically, a human. Non-human primates are also subjects. The term subject includes domestic animals, such as cats and dogs, livestock (e.g., cows, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., ferrets, chinchillas, mice, rabbits, rats, gerbils, guinea pigs, etc.). As such, veterinary and medical uses and formulations are contemplated herein. The term does not denote a particular age or sex. As such, adult and neonatal subjects, regardless of male or female, are intended to be covered. As used herein, the terms patient or subject may be used interchangeably and refer to a subject suffering from a disease or disorder. The lentivirus-like particles provided herein can be administered to a subject, for example, by injection into a subject according to known, routine methods. Exemplary administration methods include oral, rectal, transmucosal, topical, intranasal, inhalation (e.g., via aerosol), buccal (e.g., sublingual), vaginal, intrathecal, intraocular, transdermal, intradermal, intrapleural, intracerebral, and intraarticular, topical, and direct tissue or organ injection. Administration can also be to a tumor. The most suitable route in any given case depends on the nature and severity of the condition being treated and the properties of the specific lentivirus-like particles being used. In some examples, lentivirus-like particles are injected intravenously (IV), intraperitoneally (IP), intramuscularly, or into a specific organ or tissue. In some embodiments, two or more administrations (e.g., two, three, four or more administrations) may be used over variously spaced periods, e.g., daily, weekly, monthly, yearly, etc., to achieve the desired level of gene editing.

[0110] The effective amount of any of the recombinant lentivirus-like particles described herein can be varied and determined by those skilled in the art through experimentation and / or clinical trials. For example, an effective dose may be about 10 6 ~about 10 15 lentivirus-like particles, e.g., about 10 6 ~about 10 14 pieces, about 10 6 ~about 10 13 pieces, about 10 6 ~about 10 12 lentivirus-like particles, approximately 10 6 ~about 10 12 pieces, about 10 6 ~about 10 11 pieces, or about 10 6 ~about 10 11 The effective dosage may be 1000 lentivirus-like particles. Other effective dosages can be easily established by those skilled in the art through routine testing to establish a dose-response curve. See, for example, Mangeot et al. "Genome editing in primary cells and in vivo using viral-derived nanoblades loaded with Cas9-sgRNA ribonucleoproteins," Nat Commun 10, 45 (2019). https: / / doi.org / 10.1038 / s41467-018-07845-z.

[0111] In some examples, a method for modifying a target locus of interest is provided, comprising transducing a plurality of eukaryotic cells with a plurality of viral particles, the plurality of viral particles comprising (i) a fusion protein comprising a viral protein, for example, NC, MA, VRP, or NEF, wherein the viral protein comprises at least one non-viral aptamer-binding protein (ABP), and (ii) a ribonucleotide protein (RNP) complex comprising (1) a gRNA and (2) an ABE, wherein the RNP can bind (e.g., preferentially bind) to a genomic target sequence in the genomic DNA of a cell via the gRNA, and the ABE modifies the genomic DNA of the cell. As described above, the RNP is packaged into the viral particle through the interaction of an aptamer sequence attached to or inserted into the gRNA sequence, which forms a complex with a catalytically impaired CRISPR-associated endonuclease.

[0112] The described method can be used with any catalytically impaired CRISPR-associated endonuclease that requires the constant region of the sgRNA for function. These include, but are not limited to, RNA-guided site-specific nucleases. Examples include nucleases present in any bacterial species that encodes a type II or V CRISPR / Cas system. Suitable CRISPR-associated endonucleases are described throughout this disclosure. For example, but not limited to, the site-specific nuclease can be a catalytically impaired Cas9 polypeptide, a catalytically impaired Cpf1 polypeptide, a catalytically impaired Cas9 nickase, or any derivative thereof.

[0113] Generally, sgRNAs are targeted to specific regions at or near genes. In some instances, sgRNAs can be targeted to regions where a single base change is required, for example, to correct a single base mutation in the human beta-globin gene that causes sickle cell anemia. The sgRNA then directs the RNPs described herein to specific sites in the cellular genome. Once the RNPs bind to specific sites in the genome, the adenine base editor catalyzes the formation of inosine from adenosine (A) in one strand, while a catalytically impaired endonuclease, e.g., Cas9 D10A, nicks the opposing, i.e., unedited, strand. Because inosine is read as guanosine by polymerase enzymes, DNA repair and replication mechanisms replace the original AT base pair with a GC base pair at the target site. See Gaudelli et al. (2017).

[0114] In some examples, modifications to the system components described in the present disclosure do not impair the way the system components function after transduction into eukaryotic cells. Rather, the components can function similarly or better than unmodified components when transducing eukaryotic cells. For example, the viral fusion protein in a lentivirus-like particle cannot prevent the lentivirus-like particle from transducing eukaryotic cells. Similarly, if the RNP packaged in the lentivirus-like particle contains at least one aptamer sequence, the at least one aptamer sequence cannot prevent the lentivirus-like particle from transducing eukaryotic cells. In some examples, lentivirus-like particles containing viral fusion proteins can result in more gene editing when transduced into eukaryotic cells than lentivirus-like particles that do not contain viral fusion proteins. In one example, the viral fusion protein can be an NC-ABP fusion protein, such as an NC-MS2 fusion protein or an NC-PP7 fusion protein. In one example, the NC fusion protein is fused to one or two ABPs, for example, one or two MS2 proteins, one or two PP7 proteins, or one MS2 protein and one PP7 protein.

[0115] Eukaryotic cells can be in vitro, ex vivo, or in vivo. In some embodiments, the cells are primary cells (isolated from a subject). As used herein, primary cells are cells that have not been transformed or immortalized. Such primary cells can be cultured, subcultured, or passaged a limited number of times (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 cultures). In some cases, primary cells are adapted to in vitro culture conditions. In some cases, primary cells are isolated from an organism, system, organ, or tissue, optionally sorted, and used directly without culturing or subculturing. In some cases, primary cells are stimulated, activated, or differentiated. In some embodiments, the cells are cultured under conditions effective to expand a population of modified cells. In some embodiments, cells modified by any of the methods provided herein are purified. In some cases, cells are removed from a subject, modified using any of the methods described herein, and readministered to the patient.

[0116] In some examples, once cells are transduced with the viral particles described above, the cells are cultured for a sufficient amount of time to allow gene editing to occur, so that a pool of cells expressing a detectable phenotype can be selected from a plurality of transduced cells. The phenotype can be, for example, cell growth, survival, or proliferation. In some examples, the phenotype is cell growth, survival, or proliferation in the presence of a drug, such as a cytotoxic agent, an oncogene, a tumor suppressor, a transcription factor, a kinase (e.g., a receptor tyrosine kinase), a gene (e.g., an exogenous gene) under the control of a promoter (e.g., a heterologous promoter), a checkpoint gene or cell cycle regulator, a growth factor, a hormone, a DNA damaging agent, a drug, or a chemotherapeutic agent. The phenotype can also be protein expression, RNA expression, protein activity, or cell motility, migration, or invasiveness. In some examples, selecting cells based on phenotype includes fluorescent-activated cell sorting, affinity purification of cells, or selection based on cell motility.

[0117] In some examples, selecting the cells includes analyzing the genomic DNA of the cells, for example, by amplification, sequencing, SNP analysis, etc. Sequencing methods include, but are not limited to, shotgun sequencing, bridge PCR, Sanger sequencing (including microfluidic Sanger sequencing), pyrosequencing, massively parallel signature sequencing, nanopore DNA sequencing, single molecule real-time sequencing (SMRT) (Pacific Biosciences, Menlo Park, CA), ion semiconductor sequencing, ligation sequencing, sequencing by synthesis (Illumina, San Diego, CA), Polony sequencing, 454 sequencing, solid-phase sequencing, DNA nanoball sequencing, heliscope single molecule sequencing, mass spectrometry sequencing, pyrosequencing, Supported Oligo Ligation Detection (SOLiD) sequencing, DNA microarray sequencing, RNAP sequencing, tunneling current DNA sequencing, and any other DNA sequencing method identified in the future. One or more of the sequencing methods described herein can be used in high-throughput sequencing methods.As used herein, the term " high-throughput sequencing " refers to any method for sequencing nucleic acid, in which more than one nucleic acid sequence is sequenced at a given time.

[0118] Treatment method Any of the methods and compositions described herein can be used to treat a disease in a subject (e.g., cancer, a blood disorder (e.g., sickle cell anemia or beta-thalassemia), an infectious disease, an autoimmune disease, transplant rejection, graft-versus-host disease, or other inflammatory disorder).

[0119] In some methods, the cancer being treated is selected from cancer of B-cell origin, breast cancer, gastric cancer, neuroblastoma, osteosarcoma, lung cancer, colon cancer, chronic myeloid cancer, leukemia (e.g., acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or acute lymphocytic leukemia (ALL)), prostate cancer, colon cancer, renal cell carcinoma, liver cancer, kidney cancer, ovarian cancer, stomach cancer, testicular cancer, rhabdomyosarcoma, and Hodgkin's lymphoma. In some embodiments, the cancer of B-cell origin is selected from the group consisting of B-lineage acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, and B-cell non-Hodgkin's lymphoma.

[0120] In some methods, the subject's cells are modified in vivo. In some methods, a method of treating a disease in a subject includes a) obtaining cells from the subject, b) modifying the cells using any of the methods provided herein, and c) administering the modified cells to the subject. See, for example, Milone and O'Doherty "Clinical sue of lentiviral vectors," Leukemia 32, 1529-1541 (2018). Optionally, the disease is selected from the group consisting of cancer, a blood disorder (e.g., sickle cell anemia or beta-thalassemia), an infectious disease, an autoimmune disease, transplant rejection, graft-versus-host disease, or other inflammatory disorder in the subject. In some methods for treating cancer, cells obtained from the subject are modified to express a tumor-specific antigen. As used throughout, the phrase "tumor-specific antigen" refers to an antigen that is unique to cancer cells or that is more highly expressed in cancer cells than in non-cancerous cells. Optionally, the cells obtained from the subject are T cells. If necessary, the modified cells are expanded prior to administration to a subject.

[0121] The lentivirus-like particles or cells described herein can be formulated as pharmaceutical compositions. Accordingly, pharmaceutical compositions comprising any of the lentivirus-like particles described herein are provided herein. Pharmaceutical compositions comprising any of the modified cells described herein are also provided. Optionally, the pharmaceutical composition can further comprise a carrier. The term "carrier" refers to a compound, composition, substance, or structure that, when combined with the lentivirus-like particles or cells, assists or facilitates the preparation, storage, administration, delivery, efficacy, selectivity, or any other characteristic of the lentivirus-like particles or cells for their intended use or purpose. For example, the carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject. Such pharmaceutically acceptable carriers include sterile biocompatible pharmaceutical carriers, including, but not limited to, saline, buffered saline, artificial cerebrospinal fluid, dextrose, and water. Pharmaceutically acceptable means a material that is not biologically or otherwise undesirable, which can be administered to an individual in conjunction with a selected agent without producing unacceptable biological effects or interacting in a deleterious manner with other components of the pharmaceutical composition in which it is contained.

[0122] All patents, patent publications, patent applications, articles, books, technical references, etc. discussed in this disclosure are hereby incorporated by reference in their entirety for all purposes.

[0123] It should be understood that the figures and descriptions of the present disclosure have been simplified to illustrate elements relevant to a clear understanding of the present disclosure. It should be appreciated that the figures are presented for illustrative purposes and not as assembly drawings. Omitted details and modifications or alternative embodiments are within the purview of those skilled in the art.

[0124] It may be recognized that in certain aspects of the present disclosure, a single component may be replaced by multiple components, and multiple components may be replaced by a single component, to provide an element or structure or to perform a given function(s). Except where such a substitution would not be operative to perform a particular embodiment of the present disclosure, such substitution is considered to be within the scope of the present disclosure.

[0125] The examples presented herein are intended to illustrate potential and specific implementations of the present disclosure. It can be appreciated that the examples are primarily intended for purposes of explanation of the present disclosure for those skilled in the art. There may be variations to these diagrams or operations described herein without departing from the spirit of the present disclosure. For example, in certain cases, method steps or operations may be performed or implemented in a different order, or operations may be added, deleted, or modified.

[0126] Where a range of values ​​is provided, unless the context clearly dictates otherwise, it is understood that each intervening value, down to the smallest fraction of the unit of the lower limit, between the upper and lower limits of that range is also specifically disclosed. Any narrower range between any stated or unstated intervening value in a stated range and any other stated or intervening value in that stated range is encompassed. The upper and lower limits of those smaller ranges may independently be included in or excluded from that range, and each range in which either, neither, or both limits are included in the smaller range is also encompassed within the technology subject to any specifically excluded limits in the stated range. When a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.

[0127] Different arrangements of the components shown in the drawings or described above, as well as components and steps not shown or described, are possible. Similarly, some features and subcombinations are useful and may be used without mentioning other features and subcombinations. Although embodiments of the present disclosure have been described for purposes of illustration and not limitation, alternative embodiments will become apparent to readers of this patent. Thus, the present disclosure is not limited to the embodiments described above or shown in the drawings, and various embodiments and modifications can be made without departing from the scope of the following claims.

[0128] Publications cited herein, and the material for which they are cited, are hereby specifically incorporated by reference in their entirety. [Example]

[0129] Plasmid pMD2.G (Addgene No. 12259), pCMV_ABEmax (Addgene No. 112095) (Koblanet al. Nat Biotechnol 2018, 36(9): 843-846), and psPAX2-D64V (Addgene No. 63586) (Certo et al. Nat Methods 2011, 8(8): 671-6) were purchased from Addgene. Plasmids for expressing ABE7.10 in E. coli have been previously described (Kim et al., Nat Biotechnol 2019, 37(4), 430-435). Other plasmids were constructed as shown in Table 2. Gene synthesis was performed by GenScript Inc. All constructed constructs were verified by Sanger sequencing. Sequence information for primers and oligonucleotides is listed in Table 3. The oligos used to generate the ABE target sequences and sgRNA expression constructs are listed in Table 4. It is understood that the sequences for the components of the plasmids listed in Table 2 can be separated by a nucleic acid linker, e.g., a linker of about 2-100 bases. Optionally, any of the constructs described herein can include one or more introns, e.g., between the promoter sequence and the nucleic acid encoding the polypeptide sequence (e.g., ABE), to facilitate expression of one or more polypeptide sequences in the construct. Table 2. Plasmids [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] Table 3. Primers [Table 3] Table 4. Target sequences and oligos for cloning into sgRNA expression vectors [Table 4]

[0130] ABE7.10 expression and purification The SNU-ABE plasmid encoding the codon-optimized ABE7.10 linked to an N-terminal His tag was first transformed into BL21-star(DE3) competent cells, which were then plated on Luria-Bertani (LB) agar plates containing 50 μg / ml kanamycin. After overnight incubation at 37°C, single colonies were selected and grown overnight at 37°C in LB broth containing 50 μg / ml kanamycin and 10 μM ZnCl2 to maintain ABE catalytic activity (pre-culture). After this pre-culture, a portion of the inoculum was transferred to several 400 ml LB medium in 1 L flasks for large-scale cultivation (up to 6 L). The resulting culture was incubated at 37°C with shaking at 250 rpm until the absorbance A600 reached approximately 0.5–0.70. The culture was then placed on ice for approximately 1 hour. To induce ABE protein expression, 1 mM isopropyl β-D-1-thiogalactopyranoside (GoldBio, St. Louis, MO) was added, and the cultures were incubated at 18°C ​​with shaking at 250 rpm for 14–16 h.

[0131] All subsequent steps of the purification procedure were performed at 0–4°C. Prior to cell lysis, cells were harvested by centrifugation at 5,000 g for 10 minutes and then resuspended in 8 ml of lysis buffer per 400 ml of inoculum: 50 mM sodium phosphate (Sigma-Aldrich, St. Louis, MO), 500 mM 1% Triton® X-100 (Sigma-Aldrich), 20% glycerol, 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich), 1 mg / ml hen egg white lysozyme (Sigma-Aldrich), 10 μM ZnCl2 (Sigma-Aldrich), pH 8.0. For lysis, cells were frozen in liquid nitrogen and thawed at 37°C a total of three times. For further lysis, the cells were sonicated (total of 3 min, 5 sec on, 10 sec off), after which they were centrifuged at 13,000 rpm to clarify the lysate. The supernatant was mixed with 10 ml of Ni-NTA agarose beads (QIAGEN), and the resin-lysate mixture was gently rotated for 1 hour and then loaded onto a column. The column was washed three times with 50 ml of nickel wash buffer (50 mM sodium phosphate (Sigma-Aldrich), 150 mM NaCl (Sigma-Aldrich), 35 mM imidazole (Sigma-Aldrich), 1 mM DTT (GoldBio), 10 μM ZnCl (Sigma-Aldrich), pH 8.0), and the protein was then eluted with 20 ml of nickel elution buffer (50 mM sodium phosphate, 150 mM NaCl, 250 mM imidazole, 20% glycerol, 1 mM DTT, 10 μM ZnCl, pH 8.0). The eluted protein was further purified with 5 ml of heparin-Sepharose beads (GE Healthcare) in a separate column. The column was washed three times with 50 ml of heparin wash buffer (50 mM sodium phosphate, 150 mM NaCl, 1 mM DTT, 10 μM ZnCl, pH 8.0) and the protein was eluted with 20 ml of heparin elution buffer (50 mM sodium phosphate, 750 mM NaCl, 20% glycerol, 1 mM DTT, 10 μM ZnCl, pH 8.0).Finally, the eluted protein was concentrated and buffer exchanged into ABE storage buffer (200 mM NaCl, 20 mM HEPES, 1 mM DTT, 40% glycerol, pH 7.5) by centrifugation at 6,000 × g through a 100,000 kDa cutoff Amicon Ultra-4 column (Millipore).

[0132] ABE and Endo V-mediated in vitro digestion of amplified target sites The region spanning ABE site 1 (Hek2) was amplified using polymerase chain reaction (PCR, chr5:+87944480-87944802) with primers HEK2-F and HEK2-R. Two micrograms of the resulting amplicon was then incubated with 4 micrograms of ABE7.10 protein and 3 micrograms of sgRNA (targeting ABE site 1) in 200 microliters of ABE reaction buffer (50 mM Tris-HCl (Sigma-Aldrich), 25 mM KCl (Sigma-Aldrich), 2.5 mM MgSO (Sigma-Aldrich), 0.1 mM ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich), 2 mM DTT (GoldBio), 10 mM ZnCl (Sigma-Aldrich), 20% glycerol) for 1–2 hours at 37°C. After the reaction, the ABE protein and sgRNA were removed by incubation with 80 μg of proteinase K and 400 μg of RNase A (both from Qiagen) for 10 minutes, respectively. The amplicon was purified using a PCR purification kit (MGmed). 1 μg of the purified amplicon was incubated with 10 units of Endo V enzyme (NEB) for 1 hour. The mixture was then incubated with 80 μg of proteinase K and purified again using a PCR purification kit (MGmed). Finally, the DNA fragments were imaged after electrophoresis on a 2% agarose gel. RNP electroporation CRISPR RNA for ABE site 1 (rGrArArCrArCrArArArGrCrArUrArGrArCrUrGrCrGrUrUrUrUrArGrArGrCrUrArUrGrCrU) (SEQ ID NO: 74) was synthesized by IDT Inc. (Coralville, IA). Alt-R® CRISPR-Cas9 tracrRNA, Alt-R® CRISPR-Cas9 negative control crRNA, Alt-R® Cas9 electroporation enhancer, and Nuclease Free Duplex buffer were purchased from IDT Inc. RNP reconstitution and electroporation were performed according to the instructions of IDT Inc. A total of 2 × 10 5 HEK293T cells were used for each electroporation using the Amaxa Nucleofector system (Lonza, Basel, Switzerland). The cells were resuspended in 100 μl of nucleofection buffer from the Cell Line Nucleofector™ Kit V (Catalog No. VCA-1003, Lonza) and placed in an electroporation cuvette. Then, 1 μl of Alt-R® Cas9 electroporation enhancer and 5 μl of reconstituted ABE RNP were added to the cells in the cuvette. Finally, the cells were electroshocked using protocol Q-001. The cells were removed from the cuvette and cultured in growth medium for 24 hours before analysis.

[0133] Lentiviral capsid-RNP production ABE RNP-packaged lentiviral capsids were produced by a three-plasmid transfection procedure: Briefly, 13 million HEK293T cells were cultured in a 15 cm dish with 15 ml of Opti-MEM. Sixteen micrograms of the ABP-modified packaging plasmid pspAX2-D64V-NC-ABP (ABP can be MCP (MS2 coat protein, binds to the RNA aptamer MS2) (Peabody et al., Nucleic Acids Res 1992, 20 (7): 1649-55) or Com (binds to the RNA aptamer com) (Hattman et al., P Natl Acad Sci USA 1991, 88 (22): 10027-10031), 6 micrograms of the envelope plasmid (pMD2.G), and 16 micrograms of plasmid DNA co-expressing ABE and the corresponding aptamer-modified sgRNA were mixed in 1 ml of Opti-MEM. 76 μl of 1 mg / ml polyethyleneimine (PEI, Polysciences Inc., Bellevue, WA) was mixed in 1 ml of Opti-MEM® reduced serum medium. The DNA and PEI mixtures were then mixed and incubated at room temperature for 15 minutes. The DNA / PEI mixture was then added to the cells in Opti-MEM® medium. 24 hours after transfection, the medium was replaced with 15 ml of Opti-MEM® medium, and ABE RNP-loaded virus-like particles (VLPs) were collected 48 and 72 hours after transfection. The supernatant was spun at 500 g for 10 minutes to remove cell debris. The clarified supernatant could be used directly or further concentrated as described below. Transfections could also be performed in 10 cm dishes or 6-well plates using Fugene HD (Promega, Madison, WI). The amount of DNA was adjusted proportionally based on the surface area of ​​the vessel.

[0134] ABE Concentration of RNP-loaded VLPs The supernatant containing the ABE RNP-loaded VLPs was concentrated using a KrosFlo® Research 2i (KR2i) tangential flow filtration system (Spectrum Labs, catalog number SYR2-U20) using a concentration-diafiltration-concentration procedure. Briefly, 150-300 ml of supernatant was first concentrated to approximately 50 ml, diafiltered with 500-1000 ml of PBS, and finally concentrated to approximately 8 ml. The hollow fiber filter modules were made from modified polyethersulfone with a 500 kDa molecular weight cutoff. The flow rate and pressure limits were 80 ml / min and 8 psi for filter module D02-E500-05-N and 10 ml / min and 5 psi for filter module C02-E500-05-N. Capsid-RNPs were also concentrated by ultracentrifugation as previously described (Lu et al., Nucleic Acids Res 2019, 47 (8): e44.).

[0135] VLP quantification VLP concentrations were determined by p24 (lentiviral capsid protein CA)-based ELISA (Cell Biolabs, QuickTiter™ Lentivirus Titer Kit Catalog No. VPK-107, San Diego, CA). When assaying unconcentrated samples, VLPs were precipitated according to the manufacturer's instructions to prevent detection of soluble p24 protein.

[0136] Western blotting analysis of capsid and Cas9 proteins in ABE RNP VLPs 200 ng of p24 VLPs were transiently treated with 0.5% Triton® X-100 according to published procedures (Wiegers et al., J Virol 1998, 72 (4): 2846-54). Briefly, VLPs were centrifuged using a Sorvall T-890 rotor (120,000 g for 2 hours) through a step gradient containing a 1 ml layer of 10% sucrose in STE [100 mM NaCl, 50 mM Tris / HCl (pH 7.5), 1 mM EDTA] with or without 0.5% Triton® X-100, and a 2 ml cushion of 20% sucrose in STE solution. Pelleted VLP particles were directly dissolved in 100 μl of 1× Laemmli sample buffer for Western blotting or to purify RNA for RT-qPCR analysis.

[0137] The proteins in each sample were separated on an SDS-PAGE gel and analyzed by Western blotting. The antibodies used included a mouse monoclonal anti-SpCas9 antibody (ThermoFisher, CRISPR-Cas9 monoclonal antibody 7A9-3A3, catalog number MA1-201, 1:1000) and a p24 mouse monoclonal antibody for capsid protein (Cell Biolabs, catalog number 310810, 1:1000). HRP-conjugated anti-mouse IgG (H+L) (ThermoFisher Scientific, Waltham, MA, catalog number 31430, 1:5000) and HRP-conjugated anti-rabbit IgG (H+L) (ThermoFisher, catalog number 31460, 1:5000) secondary antibody were used in Western blotting. The SpCas9 RNP standard was GenCrispr NLS-Cas9-NLS nuclease from GenScript (Piscataway, NJ, catalog number Z03389S). Protein signals were visualized using a chemiluminescence reagent (Pierce, Dallas, TX) on an LAS-3000 system (Fujifilm, Tokyo, Japan). Protein amounts were quantified using densitometry (NIH ImageJ software).

[0138] RNA isolation and RT-qPCR analysis RNA was isolated from enriched capsids or cells using the miRNeasy Mini Kit (QIAGEN, Hilden, Germany, catalog number 217004). RNA was reverse transcribed into cDNA using the QuantiTect Reverse Transcription Kit (QIAGEN). For sgRNA reverse transcription, 0.6 μl of random primer provided in the kit and 0.4 μl of sgRNA-specific primer (Sp-sgRNA-R1, gcaccgactcggtgccactt (SEQ ID NO: 82), 20 μM) were used. The guide-specific forward primer ABE-g5-F (Table 2) was then used with Sp-sgRNA-R1 in SybrGreen-based RT-qPCR to detect the sgRNA. Quantitative PCR was performed on a QuantStudio™ 3 instrument (Thermo Fisher) or an ABI 7500 instrument (Thermo Fisher).

[0139] VLP transduction Approximately 10-300 ng of p24 protein was added to 2.5 x 10 VLPs grown in 24-well plates with 8 μg / ml polybrene. 4 The unconcentrated VLP supernatant was added to the transduced cells. The unconcentrated VLP supernatant was diluted with fresh medium at a 1:1 ratio to the transduced cells. The cells were incubated with the VLP-containing medium for 12-24 hours, after which the medium was replaced with regular medium.

[0140] Investigating ABE protein degradation in cells 2×10 4HEK293T cells were transduced with 100 ng of p24 from VLPs containing ABE RNP, with or without the aptamer. Twelve hours after transduction, cells were maintained in DMEM with 0.5% FBS to limit cell division. Fresh medium was replaced every 48 hours. Cells were harvested every 12 hours after transduction, and the presence of ABE protein was detected by Western blotting using anti-SpCas9 (Thermo Fisher, catalog no. MA1-201) and anti-β-actin (Sigma, A5441, 1:5000) antibodies. Relative expression of ABE was quantified by densitometry using NIH ImageJ software (version 1.49). Densitometry data was used to determine the protein half-life using the two-phase decay method in GraphPad Prism 5.0 (Graphpad, San Diego, CA).

[0141] Next-generation sequencing and data analysis The regions and primers used to amplify target DNA for next-generation sequencing are listed in Table 4. A proofreading HotStart® ReadyMix from KAPA Biosystems (Wilmington, MA) was used for PCR. Amplicons were sequenced by GeneWiz's Amplicon-EZ service. Typically, 50,000 reads per amplicon were obtained. Base editing was analyzed using the online software BE analyzer (Hwang et al., BMC Bioinformatics 2018, 19 (1): 542) and CRISPRESSO2 (Clement et al., Nat Biotechnol 2019, 37 (3): 224-22), which gave similar results.

[0142] statistical analysis GraphPad Prism software (version 5.0) was used for statistical analysis. T-tests were used to compare the means of two groups. Analysis of variance (ANOVA) followed by Tukey's post-hoc test was performed to analyze data from more than two groups. In the case of two factors, Bonferroni post-hoc test was performed after ANOVA. p<0.05 was considered statistically significant.

[0143] result RNA hotspots for detecting ABE RNA off-target activity The primary goal of this study is to find an ABE delivery method with a short duration of activity and minimal RNA off-target activity; therefore, a highly sensitive RNA off-target detection method would be useful. Currently, deep RNA sequencing is used to detect ABE RNA off-targets (Grunewald et al., Nature 2019, 569 (7756): 433-437), which is time-consuming and expensive. Recently, the RNA motif CUACGAA (SEQ ID NO: 75) was found to be the most efficient ABE RNA off-target (Grunewald et al., Nat Biotechnol 2019, 37 (9): 1041-1048). By analyzing a human sequence database, we found that the human USP38 gene contains the CTACGAA (SEQ ID NO: 76) sequence in exon 9 of its coding region (Figure 2C). RT-PCR confirmed that this gene was expressed in HEK293T cells. We analyzed whether the "CUACGAA" (SEQ ID NO: 75) sequence in USP38 mRNA is an ABE RNA off-target hotspot.

[0144] HEK293T cells were transfected with plasmid DNA expressing Cas9 nickase (negative control) or plasmid DNA expressing ABE and sgRNA (targeting ABE site 1) (Gaudelli et al., Nature 2017, 551(7681):464-471). A 444-bp USP38 cDNA spanning the predicted hotspot (primers F1 and R1 in Figure 2A) was amplified for targeted next-generation sequencing (NGS). In cells transfected with DNA expressing ABE, the highest peak of "A" to "G" change (approximately 15% of the underlined A's were changed to G) was observed at the predicted hotspot CUACGAA (SEQ ID NO: 75), along with multiple lower peaks of <5% across the entire analyzed region (Figure 2B). Similar peaks were absent in control cells with Cas9 nickase (Figure 2B).

[0145] Because NGS analysis of corresponding DNA amplified from genomic DNA of cells transfected with ABE and ABE site 1 sgRNAs revealed A-to-G changes in less than 0.02% of alleles, these "A" to "G" changes must be the result of changes in the mRNA. The changes observed in the USP38 cDNA were most likely the result of nonspecific RNA editing from adenosine (A) to inosine (I), which was recognized as guanine (G) in reverse transcription and sequencing. The most frequently observed A-to-G changes all occurred in the UA motif (Figure 2C), consistent with previous observations (Grunewald et al. 2019 Nature; Grunewald et al., 2019 Nat. Biotech.).

[0146] Focusing on the A to G change in the "CUACGAA" (SEQ ID NO: 75) motif, these changes were observed in up to 16.7% of reads from cDNA of cells transfected with DNA expressing ABE, but in 0% of reads from cDNA of cells transfected with nickase (Table 5). Importantly, when analyzing gDNA of cells transfected with ABE, only 3 of 32,025 reads with the A to G change were observed. These data indicate that the "CUACGAA" (SEQ ID NO: 75) sequence in USP38 mRNA is indeed a hotspot for ABE RNA off-targets and suggest that analyzing RNA off-targets at this hotspot will allow us to compare ABE RNA off-target activity obtained from different delivery methods. Table 5. CU / (T) in USP38 cDNA and gDNA by NGS A CGAA (SEQ ID NO: 77) to CU / (T) G Analysis of changes to CGAA (SEQ ID NO: 78) [Table 5] a CU( / T) A CGAA to CU( / T) G Only reads with changes to CGAA were counted. b All reads were derived from a single NGS sample.

[0147] ABE RNPs delivered by electroporation showed undetectable RNA off-target activity 24 hours after delivery Once the ABE RNA off-target hotspot was identified, we investigated whether delivering ABE RNPs by electroporation would result in reduced RNA off-target activity compared to DNA transfection. Recombinant ABE RNPs were prepared as previously described (Kim et al., Nat Biotechnol 2019, 37 (4), 430-435), and their activity was confirmed in an in vitro assay. 20, 10, 5, 2.5, 1.25, and 0.625 μg of ABE RNP (targeting ABE site 1) were delivered to 2 × 10 5 The RNPs were delivered into HEK293T cells. Primers specific for base-edited DNA were designed, and to validate this approach, we tested whether this qPCR assay produced approximately 6 different cycle threshold (Ct) values ​​when comparing DNA from nickase-transfected cells versus ABE-transfected cells. After 24 hours of treatment, qPCR detected on-target base edits in cells treated with 20 and 10 μg of ABE RNP, but not in cells treated with lower amounts of ABE RNP. Next-generation sequencing (NGS) was performed to examine on-target base edits in cells treated with 20 and 10 μg of ABE RNP, and 2.10% ± 0.22% (N = 3) and 1.93% ± 0.53% (N = 3) of on-target base edits were observed, respectively (Figure 1D). These were target-specific base editing events, as electroporation of ABE RNPs with random sgRNAs showed an A to G change at ABE site 1 in only 0.01% of samples. See also Lyu et al., "Adenine Base Editor Rib Nucleoproteins Delivered by Lentivirus-Like Particles Show High On-Target Base Editing and Undetectable RNA Off-Target Activities," The CRISPR Journal 4(1): 69-81 (2021).

[0148] RNA off-target activity was examined at the USP38 hotspot. No off-target RNA editing was observed at the USP38 hotspot in any of the six samples, in stark contrast to the high level (>15%) of RNA off-target editing induced by ABE plasmid DNA transfection (Figure 1C, Table 4). The data show that ABE RNPs exhibited detectable on-target DNA editing 24 hours after delivery, but no detectable off-target RNA editing.

[0149] Although delivering ABE RNP by electroporation greatly reduced RNA off-target activity, relatively low on-target base editing (<5%) occurred after electroporation of 20 μg (approximately 100 pmol) of ABE RNP, likely due to the relatively large protein size of ABE (approximately 1800 amino acid residues). It would be difficult to significantly improve on-target base editing efficiency simply by increasing dosage. Therefore, more efficient ABE RNP delivery methods are needed.

[0150] Development of ABE RNP-loaded VLPs via packaging of ABE RNP in lentiviral capsids The aptamer / ABP interaction can be used to package the Cas9 RNP into a lentiviral capsid for efficient genome editing (Lyu et al., Nucleic Acids Res 2019, 47(17):e99). Given the different sizes of the proteins in question (approximately 1800 AA for ABE vs. 1114 AA for SaCas9) and the fact that the Cas9 proteins were derived from different species (Streptococcus pyogenes for ABE vs. Staphylococcus aureus for SaCas9) and had different sgRNA scaffolds, three methods of sgRNA scaffold modification were used: 1) the MS2 aptamer replaced both the tetraloop and the ST2 loop (Figure 2A), 2) one copy of the com aptamer was used to replace the tetraloop loop, and 3) one copy of the com aptamer was used to replace the ST2 loop. The aptamer com was chosen because it was the most efficient aptamer for mediating SaCas9 RNP packaging into LV capsids. One copy of the aptamer was tested because two or more copies greatly reduced RNA stability.

[0151] ABE-RNP was packaged into LV capsids by cotransfecting HEK293T cells with three plasmids, as recently described: the envelope plasmid pMD2.G expressing the VSV-G protein, a target plasmid coexpressing ABE and various target-specific aptamer-modified sgRNAs, and a packaging plasmid modified with the corresponding ABP (pspAX2-D64V-NC-MS2 for the MS2-modified sgRNA and pspAX2-D64V-NC-com for the com-modified sgRNA). The supernatant containing the capsid / ABE RNP was used to transduce HEK293T cells. Base editing activity was then compared by qPCR.

[0152] Single-guide RNAs, sgRNAs g1 and g5, were used to target ABE sites 1 and 5, respectively. These were two sites previously shown to be successfully edited after transfection with plasmid DNA expressing the corresponding ABEs (Gaudelli et al.). qPCR was used to detect the base editing activity of capsid / ABE RNPs packaged with sgRNAs containing 2xMS2, Tetra-com, and ST2-com, respectively. At ABE sites 1 and 5, 20- to 160-fold more edited products were detected in capsid / ABE RNP-treated cells than in negative control cells (ABE-g5 RNP-treated cells as a control for ABE-g1 RNP-treated cells, and vice versa). All three ABE RNPs were functional (Figure 2B, Figure 2C).

[0153] For ABE sites 1 and 5, the 2xMS2 modification showed the lowest base editing activity. For ABE site 5, the activity of the single-copy-com modified sgRNA showed similar activity at the tetraloop and ST2 loop locations. However, for ABE site 1, the ST2-com modified RNP performed significantly better than the Tetra-com modified RNP (P<0.0001). The ST2-com modification of the sgRNA was used for further experiments. The aptamer / ABP strategy was capable of packaging and delivering functional ABE RNP into human cells.

[0154] The base editing activity of ABE RNP VLPs was examined by NGS. When targeting ABE site 1 in 2.5 × 10 HEK293T cells, 200 ng of capsid-ABE RNP p24 resulted in A to G editing in 31.85% of alleles (Figure 3). 4When targeting ABE site 5 in HEK293T cells, 108 ng of capsid-ABE RNP p24 (unconcentrated supernatant) produced A-to-G edits in 87.5% of all alleles (Figure 2D). In cells treated with VLPs targeting ABE site 5, A-to-G changes were observed in 0.02% of alleles at ABE site 1, whereas in cells treated with VLPs targeting ABE site 1, A-to-G changes were observed in 0.01% of alleles at ABE site 5. These data indicate that VLPs produced high levels of site-specific base editing.

[0155] Aptamer-dependent assembly of ABE RNP-loaded VLPs We analyzed whether the aptamer / ABP interaction was necessary for the RNP to be packaged inside the capsid as designed. We compared the ABE protein content in capsids containing ABE-g5 RNP (unmodified g5 sgRNA) and ABE-g5ST2-com RNP (ST2-com modified g5 sgRNA). To eliminate ABE protein that may have been associated with the vesicle or particle membrane, we transiently treated the particles with 0.5% Triton® X-100 buffer. This procedure reduced the capsid protein p24 by more than 100% (Figure 4A).

[0156] The ABE protein was then examined by Western blotting using SpCas9 antibodies. ABE was detected only in capsids carrying the ABE-g5ST2-com RNP, but not in capsids carrying the ABE-g5 RNP (Figure 4A). In addition, transient 0.5% Triton® X-100 treatment reduced the amount of ABE by 30-50%. Compared to a known concentration of SpCas9 protein, the amount of ABE in Triton®-treated capsids was approximately 100 pg of ABE / ng p24 (Figure 4B, considering only full-length ABE with an asterisk). 1.25 x 10 per ng p24. 7Assuming a single capsid, the number of ABE molecules per capsid was estimated to be 30 molecules per capsid.

[0157] Consistent with the lack of ABE protein in ABE-g5 RNP capsids, qPCR failed to detect base editing activity in cells treated with ABE-g5 (without st2-com) RNP-packaged capsids (Figure 4C). The data indicated that ABE association with capsids and base editing activity were aptamer-dependent.

[0158] sgRNA levels in VLPs by RT-qPCR. qPCR was performed using known concentrations of each plasmid DNA (with or without com in the sgRNA) to confirm that the com aptamer did not affect qPCR detection (Figure 4D). In VLPs treated with and without equal amounts (300 ng of p24) of Triton®, the levels of the g5ST2-com sgRNA (with com) were 35.0 ± 4.8 (N = 4) and 74.2 ± 4.8 (N = 4) times higher than those of the g5 sgRNA (without com), respectively (Figure 4E). The sgRNA qPCR data are consistent with our Western blotting data, which show that the com modification of the sgRNA increased ABE levels in capsids, while Triton® X-100 treatment reduced them. Together, the data showed that packaging of ABE proteins and sgRNA in capsids and base editing activity of VLPs all depended on com modifications of the sgRNA, confirming the role of ABP / aptamer interactions in packaging of ABE RNPs.

[0159] VLPs allow transient expression of ABE RNPs in human cells To determine the duration of ABE RNP expression in human cells, HEK293T cells were transduced with transduced ABE-g5ST2-com RNP-loaded VLPs and ABE-g5 RNP-loaded VLPs (100 ng p24 / well each), and ABE protein levels were measured every 12 hours. Western blotting detected a band of 150-250 kDa in RNP-treated cells, but not in control cells (Figure 5A), consistent with the expected size of ABE (204.7 kDa). In cells transduced with ABE-g5 RNP capsids, we observed random fluctuations in low ABE levels (<25% of the highest ABE-g5ST2-com RNP levels at all time points). In cells transduced with ABE-g5ST2-com RNP capsids, ABE levels were highest during the first 24 hours after transduction and decreased slightly between 24 and 48 hours after transduction. Between 48 and 72 hours after transduction, ABE levels decreased to approximately 25% of the levels at 12 hours after transduction, similar to the levels in cells treated with ABE-g5 RNP. At approximately 60 hours after transduction, ABE levels were half of the levels at 12 hours after transduction (Figures 5A and 5B).

[0160] In experiments examining ABE in VLPs (Figure 5A), ABE was not detected in ABE-g5 RNP VLPs. In that experiment, ABE-g5 RNP VLPs were subjected to ultracentrifugation in buffer without Triton® X-100; the VLPs used to transduce cells were not centrifuged. The low background ABE in cells transduced with ABE-g5 RNP VLPs was likely ABE in the capsid preparation. This was concentrated by the tangential low-filtration system but was not packaged into capsids and therefore could be removed by ultracentrifugation. The data confirmed the short-term expression of ABE RNP delivered by VLPs.

[0161] ABE RNP-loaded VLPs exhibited undetectable guide-independent RNA off-target activity We investigated whether ABE RNP delivered by LV capsids produced detectable RNA off-targets. ABE site 1 was targeted by ABE RNP-loaded VLPs and plasmid DNA transfection. Conditions for the two delivery methods were determined, resulting in similar on-target base editing efficiencies. On-target and off-target activity was examined 24 hours after VLP treatment, as this was the time point at which ABE levels were highest. qPCR analysis of gDNA 24 hours after treatment revealed that transfection of 250 ng of plasmid DNA exhibited gene editing activity at ABE site 1 similar to transduction of 100 ng of capsid-RNP p24. Next-generation sequencing (NGS) was performed on ABE site 1 genomic DNA and USP38 cDNA (amplified with F3 and R1 in Figure 1A). ABE site 1 DNA had a slightly higher on-target A-to-G base editing rate (14.5%) in capsid-RNP-transduced cells than in cells transfected with plasmid DNA (9.2%, Table 6). Table 6. On-target base editing at hotspots and RNA off-targets [Table 6] *P<0.05 when comparing values ​​for capsid-RNP-treated cells and DNA-transfected cells by t test.

[0162] We analyzed RNA off-targets surrounding the USP38 hotspot. Because a second peak was observed near the predicted hotspot in previous experiments (peak 2 in Figure 1B), we examined the percentage of A-to-G conversion in both peaks. In VLP-treated cells, the A-to-G conversion rate was similar to that in negative control cells, whereas a slightly higher A-to-G conversion rate occurred in both peaks in cells transfected with plasmid DNA compared to VLP-treated cells (Table 5). In this experiment, DNA transfection resulted in an RNA off-target rate approximately 20-fold lower than in previous DNA transfection experiments (0.667% vs. approximately 15% for the hotspot). The lower level of RNA off-targets in this experiment could be caused by two non-exclusive mechanisms: 1) less DNA was transfected (250 ng vs. 500 ng), and 2) RNA off-target activity was detected 24 hours after transfection rather than 48 hours. Nevertheless, although on-target DNA base editing levels were 56% higher than in cells treated by DNA transfection, delivery of ABE RNPs by LV capsids did not result in detectable RNA off-targets.

[0163] RNP off-target activity was examined 24 hours after VLP delivery because ABE RNP expression duration data indicated that ABE RNP expression was highest 24 hours after transduction (Figure 5A). RNA off-targets were also examined 48 hours after VLP delivery, and no RNA off-target activity was observed in the hotspots (Figure 6). Because ABE protein levels rapidly decreased after this time point, it is unlikely that further RNA off-target activity could be detected thereafter. Therefore, RNA off-target activity for ABE RNPs delivered by LV capsids was below the detection limit of the assay.

[0164] This study sought to find an ABE delivery method with short duration of activity, high base editing efficiency, and minimal RNA off-target activity. Two of the observations described above may help address safety concerns caused by ABE's RNA off-target activity, particularly for in vivo applications: 1) delivering ABE RNPs resulted in detectable on-target DNA base editing with undetectable RNA off-target activity, and 2) we developed a novel ABE RNP-loaded VLP with high on-target DNA base editing efficiency and undetectable RNA off-target activity.

[0165] RNPs have been used in genome editing and cytosine base editing with improved specificity (Kim et al., Genome Res 2014, 24 (6): 1012-9). However, delivery of ABE using RNPs has not been performed. As shown above, delivery of ABE RNPs was performed by electroporation, and relatively low base editing activity (<5%) was observed when using the amount of ABE RNP common to Cas9 RNP electroporation protocols. It is possible that using more ABE RNPs in electroporation could improve base editing activity. ABE RNP-loaded VLPs were developed and packaged (approximately 30 ABE RNP molecules in each capsid particle). When targeting ABE site 1 in HEK293T cells, ABE RNP electroporation resulted in a base editing efficiency of <5% at 5 pg / cell (10 μg of RNP for 2 × 10 cells), whereas ABE RNP VLP transduction resulted in a base editing efficiency of >30% at 0.8 pg / cell (approximately 20 ng of RNP for 2.5 × 10 cells). When targeting ABE site g5, a base editing efficiency of >85% was obtained at a dose of 0.43 pg / cell. Thus, ABE RNP-loaded VLPs used much less ABE protein but resulted in much more efficient base editing. This novel ABE RNP-loaded VLP is the first ABE RNP delivery vehicle to demonstrate high base editing activity and low RNA off-target activity.

[0166] In addition to high capsid assembly and base editing efficiencies (>80% editing efficiency with unconcentrated VLPs), no RNA off-target activity was observed 24 hours after VLP delivery. Pre-detection RNA off-target generation could not be excluded. However, typically, the earliest time to observe gene editing activity after VLP delivery is approximately 16 hours after transduction. Because escape from the endosomal system is a process similar to that by which VLPs enter recipient cells, a comparable time should be required for ABE RNPs to become functional after delivery. RNA off-targets, if any, may occur 16 to 24 hours after RNP delivery. This short time frame may greatly reduce the chance of generating sufficient erroneous proteins that are harmful to cells. By delivering ABE mRNA, RNA off-target activity was reduced but still detectable (Gaudelli et al., Nat Biotechnol 2020 38 (7), 892-900), and therefore, delivering ABE RNP by VLP is safer due to undetectable RNA off-target activity.

[0167] The data provided herein demonstrate that VLPs are efficient ABE RNP delivery vehicles with minimal RNA off-target activity, eliminating the need to use ABE mutants with reduced RNA off-target activity. ABEs do not exhibit detectable guide-independent DNA off-target activity. This development significantly reduces the safety risk caused by the guide-independent RNA off-target activity of ABEs, enabling efficient and safe delivery of ABE RNPs.

[0168] The VLP-mediated ABE RNP delivery method delivers only 1 / 10th the amount of RNP to each cell compared to current typical RNP electroporation protocols. This low amount of transiently expressed ABE RNP delivered by VLP should also achieve reduced guide-dependent DNA off-target activity.

[0169] In summary, ABE RNPs exhibit guide-dependent DNA base editing but undetectable guide-independent RNA off-target activity. ABE RNPs can be efficiently and functionally packaged into lentiviral capsids. VLP-delivered ABE RNPs exhibit high on-target DNA base editing activity and undetectable RNA off-target activity.

[0170] Exemplary Embodiments Embodiment 1. A mammalian expression plasmid comprising a eukaryotic promoter operably linked to a non-viral nucleic acid sequence, wherein the non-viral nucleic acid sequence comprises: (i) a nucleic acid sequence encoding an adenosine base pair editor (ABE), wherein the ABE is a fusion protein comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease; and (ii) a guide RNA (gRNA) coding sequence comprising at least one aptamer coding sequence.

[0171] Embodiment 2. The mammalian expression plasmid of embodiment 1, wherein the catalytically impaired CRISPR-associated endonuclease coding sequence encodes a Cas9 D10A protein.

[0172] Embodiment 3. The mammalian expression plasmid of embodiment 1 or 2, wherein the adenine base editor is ABE7.10 or ABE8.

[0173] Embodiment 4. The mammalian expression plasmid of any one of embodiments 1-3, wherein at least one aptamer coding sequence encodes an aptamer sequence that is specifically bound by an ABP selected from the group consisting of MS2 coat protein, PP7 coat protein, lambda N RNA binding domain, or Com protein.

[0174] Embodiment 5. The mammalian expression plasmid of any one of embodiments 1 to 4, wherein the aptamer is an MS2 aptamer sequence or a com aptamer sequence.

[0175] Embodiment 6. The mammalian expression plasmid of any one of embodiments 1 to 5, wherein the sgRNA coding sequence comprises at least one aptamer inserted into the tetraloop or ST2 loop of the sgRNA coding sequence.

[0176] Embodiment 7. The mammalian expression plasmid of embodiment 6, wherein the sgRNA coding sequence comprises at least one com aptamer inserted into the ST2 loop of the gRNA coding sequence.

[0177] Embodiment 8.a) A packaging plasmid comprising a eukaryotic promoter operably linked to a Gag nucleotide sequence, wherein the Gag nucleotide sequence comprises a nucleocapsid (NC) coding sequence and a matrix protein (MA) coding sequence, wherein one or both of the NC coding sequence or the MA coding sequence comprises at least one non-viral aptamer binding protein (ABP) nucleotide sequence, and wherein the packaging plasmid does not encode a functional integrase protein; b) at least one mammalian expression plasmid according to any one of claims 1 to 7, and c) an envelope plasmid containing the envelope glycoprotein coding sequence A lentiviral packaging system comprising:

[0178] Embodiment 9. The lentiviral packaging system of embodiment 8, wherein the packaging plasmid further comprises a Rev nucleotide sequence and a Tat nucleotide sequence.

[0179] Embodiment 10. The lentiviral packaging system of embodiment 8 or 9, further comprising a second packaging plasmid comprising a Rev nucleotide sequence.

[0180] Embodiment 11. The lentiviral packaging system of any one of embodiments 8 to 10, wherein at least one non-viral ABP nucleotide sequence encodes an MS2 coat protein, a PP7 coat protein, a lambda N peptide, or a Com protein.

[0181] Embodiment 12. A lentivirus-like particle comprising: a) a fusion protein comprising a nucleocapsid (NC) protein or a matrix (MA) protein, wherein the NC protein or the MA protein comprises at least one non-viral aptamer-binding protein (ABP); and b) a ribonucleotide-protein (RNP) complex comprising (i) an adenine base editor (ABE), which is a fusion polypeptide comprising an adenine base editor and a catalytically impaired CRISPR-associated endonuclease, and (ii) a gRNA, does not contain a functional integrase protein, Lentivirus-like particles.

[0182] Embodiment 13. The lentivirus-like particle of embodiment 12, wherein the catalytically impaired CRISPR-associated endonuclease is a catalytically impaired Cas9 protein, a catalytically impaired Cpf1 protein, or a derivative of either.

[0183] Embodiment 14. The lentivirus-like particle of embodiment 12 or 13, wherein the adenine base editor is ABE7.10 or ABE8.

[0184] Embodiment 15. A method for producing lentivirus-like particles, comprising: a) transfecting a plurality of eukaryotic cells with a packaging plasmid, at least one mammalian expression plasmid, and an envelope plasmid of the system of any one of claims 8 to 11; and b) culturing the transfected eukaryotic cells for a time sufficient to produce lentivirus-like particles.

[0185] Embodiment 16. The method of embodiment 15, wherein the lentivirus-like particle comprises (i) an adenine base editor (ABE), which is a fusion polypeptide comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease, and (ii) a ribonucleotide-protein (RNP) complex comprising a guide RNA.

[0186] Embodiment 17. The method of claim 16, wherein the plurality of eukaryotic cells are mammalian cells.

[0187] Embodiment 18. A lentivirus-like particle produced by the method of any one of embodiments 15 to 17.

[0188] Embodiment 19. A method of modifying a genomic target sequence in a cell, comprising transducing a plurality of eukaryotic cells with a plurality of viral particles, wherein the plurality of viral particles comprise the lentivirus-like particle of embodiment 12, wherein the RNP binds to the genomic target sequence in the genomic DNA of the cell, and the ABE deaminates an adenine in the genomic target sequence, thereby modifying the genomic target sequence.

[0189] Embodiment 20. The method of embodiment 19, wherein the plurality of eukaryotic cells are mammalian cells.

[0190] Embodiment 21 The method of any one of embodiments 19 or 20, wherein the plurality of eukaryotic cells are cells present in a subject.

[0191] Embodiment 22. The method of embodiment 21, wherein the subject is a human subject.

[0192] Embodiment 23 The method of embodiment 22, wherein the subject is injected with a plurality of viral particles.

[0193] Embodiment 24. A cell containing the plasmid according to any one of embodiments 1 to 7.

[0194] Embodiment 25. A cell containing the lentiviral packaging system according to any one of embodiments 8 to 11.

[0195] Embodiment 26. A cell containing a lentivirus-like particle according to any one of embodiments 12 to 14.

[0196] Embodiment 27. A cell modified using the method of any one of embodiments 19 to 23.

[0197] Embodiment 28. A method for treating a disease in a subject, comprising: a) obtaining cells from the subject; b) modifying the subject's cells using a method according to any one of embodiments 19 to 23; and c) administering the modified cells to the subject.

[0198] Embodiment 29. The method of embodiment 28, wherein the disease is cancer.

[0199] Embodiment 30. The method of embodiment 29, wherein the disease is sickle cell anemia.

[0200] Embodiment 31. The method of any one of embodiments 28 to 30, wherein the cell is a T cell. array [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6] [Table 7-7] Table 7-8 Table 7-9 Table 7-10 Table 7-11 Table 7-12 Table 7-13

Claims

1. 1. A mammalian expression plasmid comprising a eukaryotic promoter operably linked to a non-viral nucleic acid sequence, said non-viral nucleic acid sequence comprising: (i) a nucleic acid sequence encoding an adenosine base pair editor (ABE), wherein the ABE is a fusion protein comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease; and (ii) a guide RNA (gRNA) coding sequence that includes at least one aptamer coding sequence.

1. A mammalian expression plasmid comprising:

2. 2. The mammalian expression plasmid of claim 1, wherein said catalytically impaired CRISPR-associated endonuclease coding sequence encodes a Cas9 D10A protein.

3. 2. The mammalian expression plasmid of Claim 1, wherein the adenine base editor is ABE7.10 or ABE8.

4. 2. The mammalian expression plasmid of claim 1, wherein the at least one aptamer coding sequence encodes an aptamer sequence that is specifically bound by an ABP selected from the group consisting of MS2 coat protein, PP7 coat protein, lambda N RNA binding domain, or Com protein.

5. 2. The mammalian expression plasmid of claim 1, wherein the aptamer is an MS2 aptamer sequence or a com aptamer sequence.

6. The mammalian expression plasmid of claim 1, wherein the sgRNA coding sequence comprises at least one aptamer inserted into a tetraloop or ST2 loop of the sgRNA coding sequence.

7. 7. The mammalian expression plasmid of claim 6, wherein the sgRNA coding sequence comprises at least one com aptamer inserted into the ST2 loop of the gRNA coding sequence.

8. a) a packaging plasmid comprising a eukaryotic promoter operably linked to a Gag nucleotide sequence, the Gag nucleotide sequence comprising a nucleocapsid (NC) coding sequence and a matrix protein (MA) coding sequence, wherein either or both of the NC coding sequence or the MA coding sequence comprises at least one non-viral aptamer binding protein (ABP) nucleotide sequence, and the packaging plasmid does not encode a functional integrase protein; b) at least one mammalian expression plasmid according to any one of claims 1 to 7, and c) an envelope plasmid containing the envelope glycoprotein coding sequence A lentiviral packaging system comprising:

9. The lentiviral packaging system of claim 8 , wherein the packaging plasmid further comprises a Rev nucleotide sequence and a Tat nucleotide sequence.

10. The lentiviral packaging system of claim 8 , further comprising a second packaging plasmid comprising a Rev nucleotide sequence.

11. 9. The lentiviral packaging system of claim 8, wherein the at least one non-viral ABP nucleotide sequence encodes an MS2 coat protein, a PP7 coat protein, a lambda N peptide, or a Com protein.

12. a) a fusion protein comprising a nucleocapsid (NC) protein or a matrix (MA) protein, wherein the NC protein or the MA protein comprises at least one non-viral aptamer binding protein (ABP); and b) a ribonucleotide-protein (RNP) complex that includes (i) an adenine base editor (ABE), which is a fusion polypeptide that includes an adenine base editor and a catalytically impaired CRISPR-associated endonuclease, and (ii) a gRNA. A lentivirus-like particle comprising: does not contain a functional integrase protein, Lentivirus-like particles.

13. The lentivirus-like particle of claim 12, wherein the catalytically impaired CRISPR-associated endonuclease is a catalytically impaired Cas9 protein, a catalytically impaired Cpf1 protein, or a derivative of either.

14. The lentivirus-like particle of claim 12, wherein the adenine base editor is ABE7.10 or ABE8.

15. 1. A method for producing lentivirus-like particles, comprising: a) transfecting a plurality of eukaryotic cells with a packaging plasmid, at least one mammalian expression plasmid, and an envelope plasmid of the system according to any one of claims 8 to 11; and b) culturing said transfected eukaryotic cells for a period of time sufficient to allow lentivirus-like particles to be produced. A method comprising:

16. 16. The method of claim 15, wherein the lentivirus-like particle comprises (i) an adenine base editor (ABE), which is a fusion polypeptide comprising an adenosine deaminase and a catalytically impaired CRISPR-associated endonuclease, and (ii) a ribonucleotide-protein (RNP) complex comprising a guide RNA.

17. 17. The method of claim 16, wherein the plurality of eukaryotic cells are mammalian cells.

18. 16. A lentivirus-like particle produced by the method of claim 15.

19. 13. A composition for use in a method of modifying a genomic target sequence in a cell, the composition comprising a plurality of viral particles, the method comprising transducing a plurality of eukaryotic cells with the plurality of viral particles, the plurality of viral particles comprising the lentivirus-like particle of claim 12, the RNP binds to the genomic target sequence in genomic DNA of the cell, and the ABE deaminates an adenine in the genomic target sequence, thereby modifying the genomic target sequence.

20. 20. The composition of claim 19, wherein the plurality of eukaryotic cells are mammalian cells.

21. The composition of claim 19 , wherein the plurality of eukaryotic cells are cells present in a subject.

22. The composition of claim 21 , wherein the subject is a human subject.

23. 23. The composition of claim 22, wherein the subject is injected with the plurality of viral particles.

24. A cell containing the plasmid of claim 1.

25. A cell containing the lentiviral packaging system of claim 8.

26. A cell containing the lentivirus-like particle of claim 12.

27. 20. A cell modified using the method of claim 19.

28. 1. A composition for treating a disease in a subject, comprising modified cells, the modified cells comprising: a) obtaining cells from said subject; and b) modifying the cells of the subject using the method of claim 19; A composition obtained by a method comprising:

29. 29. The composition of claim 28, wherein the disease is cancer.

30. 30. The composition of claim 29, wherein the disease is sickle cell anemia.

31. 29. The composition of claim 28, wherein the cell is a T cell.